Abstracts
The Conference, hosted by the National Osteoporosis Society, offers a broad and varied programme, which will be of interest to clinicians, allied health professionals and non-clinical scientists working in the field of osteoporosis and bone health. Our plenary speakers are of international standing and reflect the multidisciplinary nature of our field. The Conference is being held at the International Convention Centre (ICC) in Birmingham, an award-winning conference venue located in the heart of Birmingham's city centre.
Programme
We have endeavoured to ensure that this year's Osteoporosis Conference comprises an exciting and varied programme including plenary lectures, clinical symposia and parallel sessions to ensure that whatever your professional background, there will be topics of relevance and interest. Clinical and non-clinical aspects of osteoporosis and bone health will be discussed, and we are confident that you will find the sessions thought-provoking and inspiring. In addition to our invited speakers there will of course be a comprehensive range of oral and poster presentations selected from submitted abstracts. A number of highly interactive workshops will address topical and clinically relevant issues including exercise and osteoporosis, bone turnover markers, renal case studies and vertebral fracture management.
Networking
A key component of the meeting will be the extensive opportunities for informal discussion and networking. We are delighted to have a number of leading pharmaceutical and healthcare companies exhibiting at the Conference. In addition, the conference dinner will provide the ideal opportunity to catch up with colleagues.
Abstracts
The response to our call for abstracts this year has been excellent. Each abstract has been marked by a panel of expert reviewers and given an overall mean score. The final abstracts will be available to view as poster presentations or in oral presentation sessions throughout the Conference. All successfully accepted abstracts are available to view via the conference app and have been published in the free limited-edition Osteoporosis International e-supplement.
Awards
This year there will be a 'Young Scientist' award, which recognises the work of an investigator pursuing research into osteoporosis and/or fragility fractures. Abstract awards will also be presented to eligible abstract authors at the meeting who achieved the highest mean review scores. The Hilary Noakes Award in Bone Densitometry and the Judith Adams award will also be presented during the conference dinner. There will also be additional prizes for highly commended poster presentations chosen by our visiting speakers at the meeting. Finally, we would like to thank you for attending and contributing to the success of this Conference, and hope you have an enjoyable and informative experience. Physical activity or exercise are often recommended in clinical practice guidelines for the management of osteoporosis. Exercise is one of the few therapies where the proposed anti-fracture mechanisms that include effects on both bone strength and applied loads, where applied loads can come in the form of a fall, externally applied loads, body weight, or muscle forces. Importantly, people with osteoporosis often have questions about the safety and efficacy of exercise. We will explore the evidence pertaining to the potential efficacy of different types of exercise for preventing fractures in people with osteoporosis, including its direct effects on outcomes along the causal pathway to fractures (e.g., falls, posture, bone strength) and what we know about safety. Considerations for future research are discussed, such as the need for trials in individuals with low bone mass. Future trials should also consider adequacy of calorie or protein intake, the confounding effect of exercise-induced weight loss, or the most appropriate therapeutic goal (e.g., strength, weight bearing, or hypertrophy) and outcome measures (e.g., fracture, disability, costeffectiveness).
middle and older age. 500,000 men and women aged 40-69 years were recruited across the UK between 2006 and 2010. The baseline assessment was extensive, and venous blood samples were collected, including DNA, which has facilitated GWAS data now available on all 500,000 participants, and ongoing exome and whole genome sequencing. A panel of standard biochemical, haematological and immunological assays has been provided for all participants, and a metabolomics panel is underway. The UK Biobank resource is linked with NHS information systems in order to capture data relating to incident disease outcomes. The Imaging Enhancement will add MRI imaging of the brain, heart and abdomen, together with DXA (whole body, lumbar spine, hips, plus vertebral fracture assessment and imaging of both hips and knees), carotid Doppler and repeat of the baseline visit, in 100,000 of the original 500,000 participants. Over 25,000 participants have been scanned to date, with the centres in Stockport and Newcastle recruiting at a rate of 18 participants per day, 7 days per week and a further centre in Reading also due. UK Biobank combines unprecedented size, breadth and depth for a prospective longitudinal cohort study. In my presentation I will describe the rationale for the UK Biobank cohort, the methodology, data available and opportunities for musculoskeletal research.
IS3 WHAT'S THE SCORE WITH VITAMINS AND MINERALS AND BONE HEALTH
Alisa Welch University of East Anglia, Suffolk, UK Micronutrient vitamins and minerals are important for both skeletal and muscle health. Low bone density, osteoporosis and sarcopenia (low skeletal muscle mass and function) are linked to increased risk of fractures during aging. It is well known that both calcium and vitamin D are important in maintaining bone health during aging, and newer evidence suggests that vitamin D is also important for maintaining skeletal muscle mass and function. The importance of other vitamins and minerals has been less investigated despite their roles in the structure, physiology and metabolism of bone. These micronutrients include vitamins C, E, carotenes and the minerals potassium and magnesium. Evidence is also growing that these micronutrients are also important for maintaining skeletal muscle mass and physical function during aging. My presentation will review the current and emerging evidence of the importance of vitamins and minerals for bone health and risk of sarcopenia and fractures. This includes examples from my research in the population studies of the EPIC-Norfolk (European Prospective Investigations into Cancer and Nutrition) cohort, The UKTwins cohort and the UK Biobank. A balanced diet sufficient in micronutrients is important both for prevention of osteoporosis and as an adjunct to medical treatment. The UK recommendations for dietary intake of vitamin D were reviewed in the government report of the SACN committee (published in 2016), and recommended an intake of 10 μg per day in adults. Since micronutrients are important, for musculoskeletal health I will review how following the healthy eating guidelines can help to achieve adequate intakes both in the general population and in those following vegan or vegetarian eating patterns. Assessing a patient for osteoporosis and increased fracture risk is the main role for the allied health professional (AHP) operating the DXA scanner. This role is predominately done by radiographers but is also performed by clinical technologists, nurses or other suitably trained health care professionals. Traditionally, the main focus of the DXA operator was one limited to acquiring good quality precise DXA scans, analysing the images and forwarding the results to a clinician to provide a report and treatment recommendations for the referrer. However, increasingly, the role of the DXA operator is being expanded in recognition of the key skills and knowledge they can bring to this diagnostic pathway and the wider osteoporosis service. Empowering the AHP to provide a role though the whole diagnostic pathway has a two-fold advantage, firstly it has the potential to significantly improve the pathway of the patient at risk of osteoporosis by providing a complete point of contact assessment and secondly, the extended role improves professional development and job satisfaction of the AHP. Areas where extended practice is being implemented can vary by centre. Examples of key activities for the expanded role are; integration with, or leading fracture liaison services, verification of DXA scan requests, reviewing patient questionnaires for risk factors and giving lifestyle advice, identifying the need for vertebral fracture assessment (VFA) from clinical suspicion and/or scan anomalies and DXA scan reporting, delivering results and ultimately treatment recommendations. By developing robust diagnostic pathways, the empowered AHP can have a significant impact in the early identification of fractures, specifically vertebral fractures which may be occult and only evident by reported height loss. Identifying osteoporotic vertebral fractures can facilitate treatment and hopefully prevent further painful and more debilitating fractures. With training and support the AHP can report these fractures and also the routine DXA scans. Sufficient development may enable the AHP to deliver the results to the patient at the time of their scan which may reduce the anxiety often felt with a delayed diagnosis. While interacting with the patient either during the scan or when discussing their results the AHP can provide lifestyle advice under the framework of Bmaking every contact count (MECC)^, advising of smoking cessation, alcohol consumption and improving physical activity. In summary, with comprehensive training, either provided locally or nationally and robust protocols DXA operators can be trained to provide a holistic high quality care package for the patient at risk of fragility fracture, enhancing both the care pathway of the patient and the professional pathway of the AHP.
IS4 IMPACT OF AN AGEING IMMUNE SYSTEM ON FRAILTY AND BONE HEALTH
to reduce the risk of future fractures. However, prediction tools such as FRAX instead utilise the femoral neck site, in part due to the technical limitations that interfere with the reliable assessment of spine BMD with DXA in older patients. These technical problems may seem insurmountable, including common patient characteristics such as body habitus, agerelated degenerative disease, kyphoscoliosis and even vertebral fracture itself. However, many of these are limitations of a 2-dimensional planar measurement of vertebral bone density only. Using clinical case studies as the basis for exploring these issues, this talk will describe the use of Quantitative Computed Tomography (QCT) using ordinary clinical CT scans in routine clinical practice at our centre. The talk will also include an update on the 2018 American College of Radiology Practice Parameters which cover the indications, reporting expectations and technical aspects of QCT spine imaging.
IS7 STRATEGIES AT EACH STAGE OF LIFE FOR PREVENTION OF FRAGILITY FRACTURE Cyrus Cooper
Medical Research Council Lifecourse Epidemiology Unit, University of Southampton; and Institute of Musculoskeletal Sciences, University of Oxford, UK Osteoporosis constitutes a major public health problem through its association with age related fractures. These fractures typically occur at the hip, spine and distal forearm. It has been estimated from incidence rates derived in North America that the lifetime risk of a hip fracture in Caucasian women is 17.5%, with a comparable risk in men of 6%. Age and sex-adjusted hip fracture rates are generally higher in Caucasian than in Asian populations. Furthermore, the pronounced female preponderance in fracture incidence observed in white populations is not seen amongst blacks or Asians in whom age-adjusted female to male incidence ratios approximate unity. Life expectancy is increasing around the globe and the number of elderly individuals is rising in every geographic region. Assuming constant age-specific incidence rates for fracture, the number of hip fractures occurring worldwide among people aged 65 years and over will rise from 1.66 million in 1990 to 6.26 million in 2050. Studies performed in the United States, Scandinavia, and the United Kingdom, between 1930 and the late 1980s, consistently reported increases in the age-adjusted incidence of hip fractures among men and women. This increase appears to have levelled off, in the northern regions of the United States, as well as more recently in Europe. Rates in Asian populations continue to show substantial rises between the 1960s and the present time. In the most recent data available from the United States, the incidence of first ever hip fracture declined by 1.37% per year among women and 0.06% per year among men. The cumulative incidence of a second hip fracture after 10 years was 11% among women and 6% among men, when death was treated as a competing risk. The reduction in hip fracture occurrence was even greater than that expected from the declining incidence of hip fractures more generally. Age-period-cohort models have suggested influences of all three contributors to these secular trends. Among current risk factors for low bone density and trauma (low body mass index, cigarette smoking, alcohol consumption, physical inactivity and dietary calcium intake) the trends are best explained by physical inactivity. Developmental contributors to peak bone and muscle mass, for example maternal nutrition and lifestyle, also appear capable of contributing to cohort effects. Finally, debate continues on the role of more aggressive osteoporosis risk assessment and therapeutic strategies in contributing to the secular decline in hip fracture rates generally. Although pharmacologic intervention might be efficacious, only a minority of hip fracture patients remain so treated, and the scope for even greater reductions in incidence remains an enticing prospect.
IS8 ATYPICAL FEMORAL FRACTURES: WHAT CAN WE LEARN FROM EPIDEMIOLOGY?
Angela Cheung University of Toronto, Toronto, Canada Atypical femoral fractures are rare stress fractures that have been associated with potent antiresorptive therapies, especially aminobisphosphonates, but can occur de-novo in patients without any bone medications. In this session, we will examine the atypical features of these fractures, their epidemiology, our current understanding of the potential pathogenetic causes. Recent data suggest that there may be genetic predisposition for the occurrence of these fractures. We will also discuss the importance of radiolographic and clinical recognition for the accurate diagnosis and timely management of these patients. Discontinuation of potent antiresorptive therapies are recommended in patients with these fractures, to facilitate fracture healing. I will also share with you what we have learned from detailed phenotypical characterization of the 350 patients in the Ontario AFF Cohort Study, and what health care providers may be able to do to prevent these debilitating fractures. Lastly, we will discuss the knowledge gaps in this area that international collaborative research may help to address in the coming years.
IS9 DEBATE: THIS HOUSE BELIEVES THAT HRT SHOULD BE FIRST-LINE TREATMENT FOR POSTMENOPAUSAL OSTEOPOROSIS IN WOMEN UNDER 60
Abstract not available IS10 INNOVATION AND DISCOVERY -THE FUTURE OF BONE HEALTH René Rizzoli Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
The reduction of higher fracture risk associated with osteoporosisrelated bone fragility implies an influence on both pathogenetic mechanisms leading to fracture, ie mechanical overload, such as falls, and mechanical incompetence, like osteoporosis. Fracture prevention measures influencing both mechanisms rely on the triad balanced nutrition/weight-bearing physical exercises/ pharmacological therapies. Only the first 2 of the triad may modify both mechanical overload and incompetence, whereas available drugs are limited so far to mechanical incompetence. All these measures are hampered by their need, to be efficacious, for long-term adherence and compliance which are rarely met. Incorrectly identified patient deserving therapy, low disease awareness, inconvenient preventive or curative regimens, and low efficacy on non vertebral fracture are all aspects needing innovative approaches. A major limitation of fall prevention is the poor long term compliance. Fall prevention with program like JaquesDalcroze eurythmics could be an approach convenient for the oldest old. Nutritional intervention modifying gut microbiota could target both bone and muscle. Available anti-osteoporosis treatments decrease vertebral fracture risk. Some reduce hip fracture risk in women with osteoporosis, but the efficacy on non vertebral fracture risk is at most 25%, except for teriparatide and abaloparatide. The monoclonal antibody against sclerostin romosozumab is likely going to join this group of drugs. Sequential therapy with sustain efficacy may be able to address the low long-term adherence. With several agents, anti-fracture efficacy can be detected as early as by 6 months of therapy indicating that a treatment should be considered even in the oldest old with a limited life expectancy, and could also be considered in those with an increased immediate fracture risk.
IS11 NATIONAL OSTEOPOROSIS LINDA EDWARDS AWARD LECTURE 2018
TOOLS TO GUIDE DECISIONS REGARDING LONG-TERM TREATMENT OF OSTEOPOROSIS Richard Eastell Department of Oncology and Metabolism, University of Sheffield and Metabolic Bone Centre, Northern General Hospital, Sheffield, UK Background: We make treatment decisions in individual patients about long-term therapy by monitoring bone mineral density (BMD) and bone turnover markers (BTM) and imaging the spine by vertebral fracture assessment (VFA). These tools can be used during long-term treatment to identify response to treatment, whether a change in treatment is merited, whether a drug holiday should be initiated or terminated. They require a statistical approach that can be used in the individual. Brief content summary: The change in BMD relates to the reduction in fracture risk with anti-resorptive and anabolic treatments for osteoporosis. We can study individuals by the statistic 'least significant change' to find out whether there has been a response in the individual. We can use a second statistical approach, a threshold (such as T-score of -2.5) to help us make decisions as to whether a drug holiday may be initiated and whether we have attained our goal of therapy (1). The weaknesses of BMD are that the increase on treatment can take several years to identify and this is not helpful in promoting adherence to treatment and that the changes in BMD during a drug holiday are small. Imaging of the spine (using spine radiographs or DXA) can be used to identify new vertebral fractures. Such a finding may indicate the need to switch treatments (for example from an anti-resorptive to an anabolic drug) or discourage starting a drug holiday in patients treated with bisphosphonates (2). The change in BTM relates to the reduction in fracture risk with antiresorptive treatments for osteoporosis (3). We can study the least significant change to identify responders and we can identify response within 12 weeks of starting antiresorptive treatment and so this can be useful in identifying failure to response, particularly poor adherence (4). We can take a threshold approach in decision-making; a BTM T-score of 0 or less is associated with the lowest risk of fracture on osteoporosis treatment and is found uncommonly in untreated osteoporosis. The LSC and threshold approaches can be used for identifying response to treatment (5). For example, more than 80% patients given the licenced oral bisphosphonates alendronate, ibandronate and risedronate respond using BTM (4). On stopping these bisphosphonates, there is a small increase in BTM (6), but on stopping other treatments such as denosumab there is a large increase in BTM (7)and this rise may help in decisions about switching to a bisphosphonate therapy. Discussion: BTM allow the identification of response to treatment and offset of response to treatment in a short time frame and so help with decisions about long term treatment. BMD are useful in identifying those patients who have reached their goal or else are ready for a drug holiday. Spine imaging is also helpful in making decisions about switching treatments or avoiding a drug holiday. References:fracture risk. Female gender was associated with higher falls risk. This suggests women of Indian ethnicity and lower income will need to be targeted for falls and fracture prevention with ageing. It will be important to re-assess this data when more participants reach older age. Figure 1 : A: % having ≥1 self-reported falls and fractures; B: % of self-reported fractures due to simple fall; C: % having ≥1 ICD-coded falls and fractures. N represents total number answering self-report question (Yes/No) Background and Objectives: Rheumatoid arthritis (RA) has previously been associated with adverse musculoskeletal outcomes. The current study aimed to explore if RA is a predictor of reduced bone mineral density and falls, using baseline data from the UK Biobank cohort. Methods: The study population comprised 500,954 people aged 37-73 years. A diagnosis of RA was identified in participants from the UK Biobank using Hospital Episode Statistics using ICD-10 codes M05 and M06. Multivariable logistic and linear regressions were used to assess the relationships with estimated bone mineral density (eBMD) as assessed by heel ultrasound, and with falls (occurring in the year prior to baseline interview, and recorded by self-report). Results: Of 500,954 participants (median age 58 years (IQR 50-63)), 5476 (1.1%) were found to have a diagnosis of RA. 321,904 participants had heel ultrasound measurements performed generating a mean eBMD T-score of -0.32. Data were available for self-reported falls in 499,956 participants, of which a total of 99120 (19.8%) had fallen in last year, with 65968 (13.2%) having had just one fall and 33152 (6.6%) having had more than one fall. A diagnosis of RA was positively associated with having a lower eBMD (mean diff. T-score -0.346, 95% CI -0.386, -0.306 p<0.01, adjusted for sex). Furthermore, individuals with a diagnosis of RA were also significantly more likely to report a fall in the last year than those without (OR 2.01, 95% CI 1.90, 2.13 p<0.01, adjusted for sex). These observations remained significant after adjustment for potential confounders (age, ethnicity, BMI, smoker status and activity). Conclusions: In this cross-sectional analysis, RA was associated with lower eBMD and an increased likelihood of falls. As both low eBMD and falls are independent risk factors for fracture, these data may help inform future strategies for reducing fracture risk in individuals with RA. This research has been conducted using the UK Biobank Resource. (04/2011-03/2015) and Office for National Statistics mortality data, to identify patients admitted with hip fracture, aged 60+ years. Deprivation was measured as Index of Multiple Deprivation quintiles; Q1-least deprived; Q5-most deprived. Charlson score measured comorbidity. Associations between deprivation and 30-day mortality and emergency 30-day readmission are described using odds ratios (ORs); logistic regression adjusted for age, gender and comorbidity. Mean 'superspell' length-of-stay(LOS) in acute plus rehabilitation hospitals, and total bed occupancy within 1-year post fracture were calculated; associations with deprivation were estimated using linear regression. Background: Meas urement of s erum concentrations of phylloquinone (vitamin K1), the primary dietary and circulating form of vitamin K, reflects intake, absorption, metabolism and provides information on its relative bioavailability. Some epidemiological studies have reported that lower serum concentrations of phylloquinone may lead to adverse outcomes on bone mineral density (BMD) and increase fracture risk. However, there is currently no established threshold of serum phylloquinone that indicates insufficiency or deficiency for its physiological effects not related to coagulation such as in the maintenance of bone health, particularly in high risk populations. Objective: The aim of the study was to determine the range of serum phylloquinone and examine the association between vitamin K1 status with bone mineral density (BMD) and fracture risk in post-menopausal women with osteoporosis (PMO). Methods: We studied 349 women with PMO aged (mean [SD] ) 68.4 [7.36] years treated with oral bisphosphonate. Demographic data were obtained through a questionnaire. BMD was measured at the lumbar spine (LS), femoral neck (FN) and total hip (TH). Blood was obtained for the determination of Vitamin K1 in serum. Results: Serum phylloquinone in the whole population was 0.56 [0.49] ug/L. There was no significant association between BMD and serum phylloquinone at any sites. One hundred and seven women had no history of previous fractures (30%; Group A) and 242 had sustained one or more fractures (70%; Group B).Serum phylloquinone was significantly lower in Group B (Group A : 0.64 [0.64] ug/L, Group B : 0.52 [0.4] ug/L, p=0.045). Vitamin K1 was independently associated with the risk of fracture, following correction for confounders including age, BMI, lifestyle factors, menopausal age and vitamin D status (p=0.032). The adjusted odds ratio (95% CI) per ug/L increase in serum vitamin K1 was 0.529 (0.291-0.946). Discussion: Vitamin K1 is lower in post-menopausal women with a history of fractures and is independently associated with the risk of fracture. Conclusions: Higher concentrations of phylloquinone may be required for the maintenance of bone health and fracture reduction in PMO. Background and Objectives: Maternal bone turnover markers in pregnancy are poorly characterised. In the Maternal Vitamin D Osteoporosis Study (MAVIDOS) we investigated: i) changes in maternal urinary C-terminal telopeptide of type I collagen (CTX) concentrations in pregnancy, and the effect of gestational vitamin D supplementation on these; and ii) associations between CTX and maternal postnatal bone indices. Methods: MAVIDOS is a randomised, double-blind, placebocontrolled trial of 1000 IU/day cholecalciferol vs placebo from 14 weeks gestation to birth. Maternal second void urinary α and β CTX (ELISA, Immunodiagnostic Systems, Boldon, UK) was measured at 14 and 34 weeks gestation. Maternal DXA (Hologic Discovery) was performed within 2 weeks of delivery. Median values were compared using Wilcoxon ranksum test; Spearman's rank correlation and linear regression were used to explore associations between CTX standardised to an SD scale and maternal bone outcomes. β-coefficients represent change in outcome per SD increase in CTX. Results: In the 636 women studied (314 placebo, 322 cholecalciferol), median (IQR) CTX (pg/ml) increased from 14 to 34 weeks in both groups (223.8 (155.0-308.6) to 445.3 (317.6-657.3), P<0.0001, and 217.5 (154.5-305 .2) to 420.0 (252.2-608.5), P<0.0001, in the placebo and cholecalciferol groups, respectively); the higher 34 week CTX in the placebo group was of borderline statistical significance (p=0.06). CTX values at 14 and 34 week values were correlated in both placebo (r=0.32) and treatment (r=0.45) groups (both p<0.0001). Overall, greater 34-week CTX was associated, similarly in either group, with lower maternal femoral neck bone area [-0.43cm 2 /SD (-0.80, -0.07), p=0.02] and bone mineral content (BMC) p=0 .03] and lumbar spine BMC [-1.29g/SD (-2.42, -0.16 <0.001), p=0.03], with associations given for groups combined. Conclusion: We have shown that a marker of bone turnover, urinary CTX, rises from early to late pregnancy. This rise appears to be reduced by gestational cholecalciferol supplementation, and is inversely associated with maternal bone mass post-partum. These findings inform our understanding of bone resorption in pregnancy and its potential relationship with vitamin D metabolism. Discussion: These findings demonstrate that both sunlight exposure and VitD supplementation contribute greatly to adequate concentrations of 25OHD and that the recommended dose for each should take into consideration the availability of the other. The strength of these results is the novel analysis that directly links human in vivo individual and habitual sunlight exposure and 25OHD concentrations, within two VitD supplementation parallel RCTs. Conclusion: This is the first study to show the effect of directly measured sunlight exposure and increased oral VitD intake (through supplementation), using identical methodologies in two opposite latitudes and in populations of the same ethnicity and gender. Although this study indicates that recommendations should be country specific, daily 15 μg vitamin D 3 was shown to be effective to significantly raise VitD concentrations throughout wintertime, regardless of latitude, with important implications for bone health through the concomitant lowering of PTH. Background: Circulating cortisol levels increase slightly with age but levels of dehydroepiandrosterone sulphate (DHEAS) decline rapidly from the age of 30 years. As cortisol is primarily catabolic and DHEAS is converted to the anabolic steroid DHEA, this increase in the cortisol:DHEAS ratio with age may have significant implications for bone health. Objective: To examine the longitudinal associations between morning cortisol and DHEAS, in relation to bone microarchitecture outcomes in a population-based UK cohort of older adults. Methods: Analyses were based on a sample of 339 communitydwelling older persons (aged 59-70 years at baseline). At baseline, serum cortisol and DHEAS levels were measured by ELISA (IBL international, Hamburg, Germany). High resolution peripheral quantitative computed tomography (HRpQCT) imaging of the radius and tibia (XtremeCT,voxel size 82 μm) was performed at follow-up (median follow-up time: 11.6 years ). Gender-adjusted linear regression was used to examine the relationships between cortisol, DHEAS and cortisol:DHEAS ratio, in relation to bone microarchitecture outcomes, with and without adjustment for anthropometric and lifestyle factors. Results: Higher cortisol was associated with higher radial cortical porosity and pore volume in fully-adjusted analyses only (p<0.03). Higher DHEAS was associated with higher tibial cortical BMD and trabecular thickness, and lower tibial total and trabecular area in gender-adjusted analyses (p<0.04); the association regarding trabecular thickness remained significant in fully-adjusted analyses. In gender-and fully-adjusted analyses, higher values of the cortisol:DHEAS ratios were associated (p<0.04) with lower values of the following tibial parameters: cortical BMD, total volumetric BMD and trabecular thickness. Discussion: Our work identifies the hypothalamo-pituitatry-adrenal (HPA) axis as a contributor to bone microarchitecture and musculoskeletal phenotype and suggests a particular role for DHEAS. These findings build on previous work performed using DXA and further dissect the relationship between the HPA axis and bone parameters. Conclusion: This study highlights interesting relationships between bone microarchitecture and the HPA axis. These may have future therapeutic implications; however, future research is required to further investigate these associations. The GLOW study is a prospective, multinational study of the epidemiology and pathogenesis of fractures in postmenopausal women aged 55y and over. Women participating the UK arm of GLOW underwent DXA and high-resolution pQCT scans. Previous work in GLOW reports associations between obesity and bone microarchitecture in relation to fracture. The aim of this work was to assess relationships between body composition and bone microarchitecture in UK-GLOW participants. UK-participants had measurements of the distal radius and tibia using HRpQCT (XtremeCT I, voxel size 82 μm) and DXA scans of the whole body (Hologic Horizon W). Linear regression was used to examine the relationship between bone microarchitecture outcomes and lean, and fat, mass index (LMI and FMI, kg/m 2 ) residuals with and without adjustment for anthropometric and lifestyle characteristics, and use of antiosteoporotic medications, and hip BMD. Fully-adjusted associations are presented below. 370 women (mean [SD] age 70.4 [5.3] years) underwent scans. Greater LMI residuals were associated with greater total and trabecular area of the radius and tibia (all p<0.02). Greater FMI residuals were associated with reduced total and trabecular area, higher trabecular number and lower separation (all p<0.02) at the radius. At the tibia, greater FMI residuals were only associated with higher cortical area (p=0.04) and lower trabecular thickness (p=0.03). After mutual adjustment, LMI and FMI show independent relationships with bone microarchitecture. LMI was associated with bone size, indicative of the response of bone to muscle loading. The strongest and most consistent associations between FMI and bone were with bone outcomes at the radius, potentially indicating non-mechanical relationships between fat and bone. Background: Drug holidays for 1-2 years have been suggested in patients on alendronate, the impact of stopping treatment on bone mineral density (BMD) levels in a clinical service has not been fully evaluated. Objective: To determine if those subjects with a better response at the femoral neck (FN) lost bone more slowly during a drug holiday. Methods: 178 postmenopausal women who had received alendronate for >4years with BMD measurements at the FN pre-alendronate treatment. FN and lumbar spine (LS) BMD as well as the bone turnover marker uNTx were measured at discontinuation and follow-up clinic appointments. Subjects were divided into 2 groups, poor and good responders (≤0.5% vs >0.5% increase in FN BMD per year of treatment). Results: There was no difference in age between the 2 groups but the good responders had received alendronate for a shorter time (median 8 vs 9years; p<0.001). There was no difference in FN or LS BMD pretreatment but the good responders also had a higher increase in LS BMD per year (mean 1.63% vs 0.67%; p<0.001). LS BMD was not significantly different between the groups at any time-point. uNTx levels were significantly lower at discontinuation (median 23 vs. 27.1; p=0.034) in the good responders but there was no difference at year 1 or year 2 post-discontinuation. FN BMD was higher at discontinuation in the good responder group (mean 0.65 vs 0.60; p>0.001) and at year 1 (median 0.64 vs 0.57; p<0.001) but not year 2. FN BMD levels fell over time with the percentage decrease per year falling more in the good responder group at year 2 (mean -0.71% v. -1.44%; p=0.03). Discussion: Subjects with a better response to treatment at the FN also showed a larger increase in LS BMD on treatment. FN BMD loss was increased at year 2 in the good responder group suggesting that the mechanisms involved in accruing bone during treatment may also result in greater bone loss during discontinuation. Conclusion: A better response to treatment resulting in higher FN BMD at discontinuation did not protect FN BMD levels but conversely resulted in greater bone loss off treatment. Background: Adolescence is a crucial period for bone development and exercise can optimise bone health however, there is a lack of scientific evidence on how popular sports of different loading can affect bone development during adolescence and how it can be improved. Objectives: The PRO-BONE study aimed to (1) investigate the crosssectional (baseline) and longitudinal (12-months) effects of football (weight-bearing sport), swimming and cycling (non-weight-bearing sports) on bone mass, bone geometry, bone texture and bone stiffness in adolescent males; and to (2) examine the effect of a 9-month jumping intervention programme on bone acquisition in adolescent males involved these sports. Methods: A total of 121adolescent males (41 swimmers, 37 footballers, 29 cyclists and 14 controls) aged 12-14 years at baseline were measured at three time points over 21-months (baseline, 12-months and 9-months of jumping intervention). Bone mineral content (BMC) and density (BMD) were measured using dualenergy x-ray absorptiometry (DXA) at total body, femoral neck and lumbar spine. Bone geometry and texture were measured using hip structural analysis and trabecular bone score respectively. Bone stiffness was measured using quantitative ultrasound. Results: The baseline findings showed that footballers have significantly better bone status than swimmers, cyclists and controls (7 to 21 %). The 12-months findings show that development of BMC (5 to 8 %) and geometry (4 to 10 %) is significantly higher in adolescent male footballers compared to swimmers and cyclists. The 9-month jumping intervention improved the acquisition of BMC, geometry and texture in adolescent males involved in swimming and cycling (4 to 13 %), but not in those engaged in football. Discussion/Conclusion: Collectively, the PRO-BONE study indicates that adolescents participating in football have higher bone status and development than cyclists and swimmers, and that a 9-month jumping intervention can improve bone development in those involved in nonweight-bearing sports. Introduction: Hip fracture anaesthesia and surgery are now so successful that nearly all patients have prompt and effective repair of their injury and most will get out of bed by the day after operation. However, frail and older patients' subsequent recovery of mobility and independence depends on the quality of care provided by the ward's multidisciplinary teams. Methods: In May-October 2017 the Chartered Society of Physiotherapy led work by over 580 physiotherapists -providing data for 5,989 (78.6%) of the 7,621 people who the National Hip Fracture Database recorded as presenting to 127 hospitals during this period. To capture the patient's experience of therapy physiotherapists were asked: BFor how long was the patient mobilising or receiving physiotherapy?f or each day in the first week after surgery. Results: On average each patient received 118 minutes of physiotherapy in the first week -27 minutes on the day after surgery reducing to 14 minutes by the end of the week. This required over three and a half hours of staff time -two hours of this being trained physiotherapist time. Staff time varied across the country -from less than an hour in some units, to several hours in others. On average half (48.6%) of people who were admitted from their own home or sheltered housing were able to return there directly from the acute ward. Acute wards which provided more therapy were more likely to get patients up on the day after surgery, less likely to transfer them to another ward for rehabilitation, and returned more patients straight home. Conclusion: Hospitals should look beyond the usual focus on the promptness of surgery, and examine the intensity of therapy they are providing, using the Hip Sprint results at www.nhfd.co.uk. However, the amount of therapy a patient receives is not just a matter of the availability of physiotherapists. Units which provide high quality perioperative surgical, anaesthetic and medical care will minimise the number of patients who are too unwell to receive therapy. Methods: A gap analysis tool was used, on request, to measure service provision against the standards. Data was collected at 32 sites in the UK, and repeated at a later date. After the baseline gap analysis, services developed improvement plans addressing gaps in provision. Following the second gap analysis, comparative analysis was undertaken to identify improvements made.
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Results:
Discussion: Improvements were seen in the systematic identification of all fragility fractures, with the notable exception of vertebral fractures which poses the greatest challenge to clinicians, requiring close collaboration with diagnostic imaging departments. Service improvement plans after first gap analysis resulted in conspicuous improvement in the review of staff training and competencies. The progress in follow-up of patients shown is essential in order to improve adherence to treatment, and thereby realise the full clinical and cost benefit of services. Conclusion: Gap analysis followed by an improvement plan has resulted in improvements in the quality of services provided. Objective: Examine whether BP use increases risk of stage progression (SP) (including dialysis and transplant), acute kidney injury (AKI), gastrointestinal events (GIE) and hypocalcaemia. Methods: Patients with an estimated Glomerular Filtration Rate <45 were identified from two homogenous electronic medical record datasets CPRD (UK) and SIDIAP (Spain). Those exposed to BP were calliper matched (width 0.02) to up to 5 controls using propensity scores stratified by duration in study. For each outcome, patients were censored at the first event, 210 days after the last BP prescription, switching to BPs or alternative treatment, dropout, death or 10 years. Absolute incident rates were calculated per 10,000 person years. Hazard ratios (HRs) of BP user were estimated using Cox regression. Analyses undertaken in individual datasets and combined using fixed effect meta-analysis. Results: In CPRD 6,309 exposed patients matched to 24,966 unexposed patients. SIDIAP: 4,143 and 20,165 respectively. Balance was <0.1 in both datasets. Rates and HR (95% CI) for each dataset shown below (Table) . For SP 5,078 events in CPRD and 6, 357 Background: Despite clinically and cost-effective therapies, most patients do not receive effective secondary fracture prevention after a fragility fracture. FLSs are recommended to close this treatment gap. To be effective, an FLS must consistently target bone protection therapies at those at high fracture risk. Objective: To compare treatment recommendations after a fragility fracture between FLSs and identify the patient and organisational-level determinants. Method: We used data from a national patient-level audit for all patients submitted in 2016. Mixed-effect logistic regression were used for analyses for individual FLS and patient-level characteristics. Results: 44,139 patient records were included, 78% female and 42% aged ³ 75 years. 50 FLSs each submitted 64 to 3116 cases. FLSs ranged from 0.25 to 4.5 WTE of nurse time, and 46% had a band 6 or lower as the most senior nurse grade. Overall 38% of patients were recommended or referred for treatment, with highest rates following an index hip (43%), spine (36%) and then non-hip non-spine (18%) fracture. Men were less likely to be treated ) and those aged ³ 75 years more likely (OR 2.91 (2.77-3.05)). FLS remained a significant predictor of treatment even after adjusting for patient-level characteristics (OR 2.37 (1.54-3.76)). Differences in treatment recommendation or referral between FLSs was not explained by seniority or number or seniority of nurses or volume of cases ( Figure) . Background: Compliance and persistence with oral bisphosphonate (oBP) treatment are poor and issues often occur early. The use of bone turnover markers (BTM) has been proposed to evaluate early treatment response and improve compliance. Most oBP prescribing is undertaken in primary care. Serum PINP became available to primary care in our locality in 2011 and we previously showed reasonable uptake (2012: 70% baseline, 32% at 6m). Objective: To evaluate the impact of early monitoring on long-term outcomes. Methods: Patients who attended for DXA after 01.01.12; and whose DXA report included standardised text recommending treatment and PINP monitoring; and who had follow-up DXA 4 to 6 years (5y) after baseline were identified. Data were collated from clinical records. PINP response was defined as a decrease exceeding least significant change (>10μg/L) and/or by follow-up PINP <35μg/L. Results: We include results from the first 200 eligible patients examined consecutively (182 F, 18 M; ages 46-90, mean 69 years). 5 patients did not start treatment for documented reasons and 49 switched to parenteral treatment. By 5y, 121 were still prescribed oBP and 25 had either never taken or had stopped oBP. Of these 146, 99 patients had at least one PINP measurement within 12m of first DXA, and 85 had both baseline and repeat PINP. 75 patients fulfilled criteria for PINP response (PINPresp+). 71 did not respond or were not monitored (PINPresp-). Reliable DXA measurements were available at both baseline and 5y for 112 patients at spine (LS) and 135 at hip (TH). BMD increase at 5y was greater in PINPresp+ compared to PINPresp-at both LS (7.0+/-5.7% v 4.1+/-7.1%, P=0.02) and TH (1.9+/-5.3% v -0.8+/-5.6%, P=0.005). Discussion: We have demonstrated that patients who were monitored and shown to have an early biochemical response to oBP treatment had significantly greater BMD improvement after 5y compared to non-responders and those who did not have early monitoring.
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Conclusion:
We conclude that early BTM monitoring in primary care has the potential to be cost-effective and improve long term fracture outcomes. Objective: The aim of this baseline audit was to assess practice concordance with recommended treatment periods and reviews. The objectives were to identify whether patients were recorded as receiving appropriate bisphosphonate drug 'holidays' depending on their risk status at 5 and 10 years after initiation. Methods: A search was conducted in the EMIS Web clinical information system to identify patients with repeat prescriptions for drugs affecting bone metabolism. The start dates for oral bisphosphonate treatment, highrisk factors (age ≥75 years, previous hip and vertebral fractures, steroid use), and review data were obtained.
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Results:
Discussion: This audit suggests an important gap in reviewing patients on bisphosphonates, resulting in potential over-use. Clearly-recorded bisphosphonate initiation and review dates and risk factors in primary care information systems would facilitate timely treatment reviews and consideration of appropriate 'drug holidays' at the 5-and 10-year review points. Conclusion: The NOGG guidelines and our review flowchart provide a good basis for primary care review and audit of oral bisphosphonates. Action to improve routine review of people prescribed oral bisphosphonates should be prioritised. Background: Despite major advances in the treatment of osteoporosis, a treatment gap exists, and barriers in treatment initiation and adherence are complex. Objectives: We aimed to investigate the effect of a population based, primary care-led fracture risk screening intervention, on initiation of anti-osteoporosis medication (AOM), and subsequent adherence. Methods: The 'Screening for prevention of fracture in older women' (SCOOP) study was a UK multi-centre RCT of screening for osteoporotic fracture risk. 12,483 women (70-85 years) identified from primary care lists, were randomised to either assessment using the FRAX tool +/-DXA BMD, with medication recommended for those found to be at high fracture risk, or to usual NHS care. Self-reported AOM use was obtained by postal questionnaire at 6, 12, 24, 36, 48 and 60 months. Ordered logistic regression was used to explore baseline determinants of adherence (defined as % study visits at which participants reported taking AOM, following a positive report at the index visit). Results: The mean (SD) age of participants was 75.6 (4.2) years, with 6233 randomised to screening and 6250 to the control group. At 6 months, 73.8% of participants classified at high fracture risk reported taking AOM (and 12.3% of all screening participants), compared with 2% of all participants in the control group. 37.1% in the screening group on treatment at 6 months were still treated at 60 months; the respective figure for the control group was 21.6%. For those participants commenced on treatment later during followup, rates of adherence at 60 months became increasingly similar between intervention and control participants (e.g. 70.3% vs 68.1% respectively at 60 months for treatment initiated at 48 months). Older age was associated with lower adherence [OR 0.96 (95%CI: 0.93 primary-care based SCOOP screening study targeted treatment to those at highest hip fracture risk using FRAX hip fracture probabilities. Objective: We wished to examine the impact of the screening intervention on hip fracture risk according to baseline FRAX hip fracture probability. Methods: The SCOOP study comprised a two-arm randomised controlled trial in women aged 70 to 85 years comparing a screening programme versus usual management. In the screening arm, treatment was recommended in women identified to be at high risk of hip fracture by FRAX (including BMD) using age-dependent intervention thresholds. Results: Of 12 483 eligible women, 6233 were randomised to screening, with treatment recommended in 898 (14.4%). In the screening arm, the number of incident hip fractures was lower than that in the control arm (218 vs 164) reflecting a 28% reduction in hip fracture risk (hazard ratio 0.72, 95%CI 0.59 to 0.89, p=0.002). As treatment was targeted to those at highest risk, the effect on hip fracture increased significantly with baseline FRAX hip fracture probability (p=0.021 for interaction); for example at the 10 th percentile of baseline FRAX hip probability (2.6%), hip fractures were not significantly reduced (HR 0.93, 0.71-1.23) but at the 90 th percentile (16.6%), there was a 33% reduction (HR 0.67, 0.53-0.84). The 10 th , 50 th and 90 th percentile values of baseline hip fracture probability in the high risk group and the associated hazard ratios for incident hip fracture are shown in the Table. Conclusion: Women identified to be at high fracture risk based on FRAX hip fracture probability are responsive to appropriate osteoporosis management. Community-based screening using the FRAX tool is feasible and effective.
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P1 T H E U T I L I T Y O F T H R E E B O N E M A R K E R S F O R MONITORING ANTI-RESORPTIVE THERAPY
Alan Courtney Clinical Biochemistry, North West London Pathology, Imperial College Healthcare NHS Trust, London, UK Introduction: Bone markers are useful, non-invasive, repeatable, cheap tests that are sensitive to early changes in bone turnover. They are commonly used to monitor the response to therapy for osteoporosis. The osteoporosis clinic routinely utilises three routine markers that our bone marker service offers: urine N-telopeptide (NTx), serum bone specific ALP (BALP) and serum total procollagen type-1 N-terminal peptide (P1NP). Aim: Here we review the utility of these three markers in monitoring bisphosphonate therapy in the osteoporosis clinic. Are there specific advantages to the measurement of combinations of markers, or is the measurement of a single marker sufficient? Methods: 5 years of bone marker data from the osteoporosis clinic at Imperial College Healthcare NHS Trust, was extracted from our Clinical Biochemistry data repository. Data was anonymised, and the following inclusion criteria were used: females who were on, or had been on bisphosphonates (excluding those on anabolic therapy where known) and those with multiple bone marker measurements for at least two out of the three of urine NTx, serum BALP and serum P1NP. Significant changes in these markers were compared.
Results: These data suggest that measurement of NTx and P1NP are sufficient to identify those with significant changes in bone turnover. Compared to P1NP, NTx may potentially be superior for identifying earlier increases in turnover. Both NTx and P1NP appear to detect decreases in turnover equally well. Both markers occasional out-perform one another in some individuals suggesting that measurement of both a resorption and formation marker may be advantageous. The measurement of BALP does not appear to add value in the management of patients on anti-resorptive therapy. Discussion and Conclusions: There appears to be merit in measurement of both serum P1NP and urine NTx for serial monitoring of patients receiving anti-resorptive therapy. Although BALP does not appear to provide any additional benefit in these patients, this marker has been shown to be useful in other cases of metabolic bone disease, such as Paget's. Background: Medication related osteonecrosis of the jaw (MRONJ), is a rare adverse effect of anti-resorptive or anti-angiogenic drug therapy that can cause significant morbidity; commonly prescribed drugs, such as bisphosphonates, used to treat a variety of cancers and osteoporosis have been associated with MRONJ. A multidisciplinary approach to the promotion and prioritisation of preventative strategies to ensure patients are dentally fit prior to the prescription of implicated medications is recommended. Current evidence suggests that patients have limited knowledge relating to MRONJ and that preventative strategies are rarely implemented. Objective: To explore the impact of MRONJ on quality of life and to explore the attitudes and perceptions of patients towards the multidisciplinary approach to the prevention of the condition. Methods: Using a Grounded Theory approach and integrating a process of constant comparison in the iterative enrichment of data sets, semi-structured interviews were undertaken, transcribed and analysed using Ritchie and Spencer's (2002) Framework Analysis. 23 patients; 6 patients with MRONJ, 13 patients prescribed a bisphosphonate and 4 patients with osteoporosis not currently prescribed any medication were recruited from primary care general medical practices and secondary care dental services in England. Salient themes were identified and related back to extant literature in the field Results: Five salient and inter-related themes emerged: (1) quality of life, indicating the physical, psychological and social impact of MRONJ; (2) limited knowledge, indicating limited awareness of the condition, risk factors and preventative strategies; (3) patient specific, referring to the complexity of patients, polypharmacy, prioritising aspects of care and personal responsibility; (4) interprofessional management, indicating a perceived organisational hierarchy, professional roles and responsibilities, articulation of risk and communication; (5) wider context, indicating potential demands on NHS resources, and barriers to dental care. Conclusions: MRONJ has a significant impact on quality of life yet appropriate preventative education is not apparent. Effective interprofessional patient education and prevention to mitigate against the risk of developing MRONJ is required. Conclusions: The majority of acutely unwell patients in hospital are vitamin D deficient/insufficient. All age groups were affected. Patients admitted to general surgical specialities tended to have lower vitamin D concentrations. We are characterising relationships with clinical outcomes and we aim to refine supplementation strategies in the acutely ill. Practice, Chartered Society of Physiotherapy, London, UK Introduction: In May-October 2017 the national audit of hip fracture physiotherapy 'Hip Sprint' provided data capturing the experience of over 5,989 patients -78.6% of all patients in 127 hospitals. This identified variation in both physiotherapy practice and service delivery. As a result 'Hip Sprint 2' was launched and includes the development of quality standards which address these priority areas. Methods: Current national standards relating to hip fracture physiotherapy including NICE guidance on hip fracture (CG124) and intermediate care (NG74) and Chartered Society of Physiotherapy (CSP) quality assurance standards, were reviewed to ensure there was no duplication.
P2 THE ATTITUDES AND PERCEPTIONS OF PATIENTS TOWARDS THE MULTIDISCIPLINARY APPROACH TO THE P R E V E N T I O N O F M E D I C A T I O N R E L A T E D OSTEONECROSIS OF THE JAW (MRONJ); A QUALITATIVE STUDY IN ENGLAND
P4 DEVELOPMENT OF PHYSIOTHERAPY STANDARDS FOR REHABILITATION AFTER HIP FRACTURE
Results: Hip Sprint identified a series of priority areas -early assessment and mobilisation -the intensity of rehabilitation offered -poor quality of handover and continuity between care providers -physiotherapists' engagement in the hip fracture programme governance. These were discussed by a group of specialist physiotherapists and patient representatives, and are now being consulted on the CSP's interactive network (iCSP) with a view to publication this year. & Physiotherapists should record their assessment findings and rehabilitation plans in the shared record to enable clear communication with We believe that that these standards will help focus clinical teams' and health managers' attention on areas of practice that have the greatest potential to improve patients' experience and outcome.
P5 MANAGING OSTEOPOROSIS AFTER BISPHOSPHONATE RELATED SUBTROCHANTERIC FRACTURES: A CASE SERIES
Eleanor Lunt, Namal Weerasuriya Health Care of Older People, Queen's Medical Centre, Nottingham, UK Background: Subtrochanteric fractures associated with longterm bisphosphonate use are rare but becoming more widely recognised. Postfracture osteoporosis, in the context of frailty, frequent falls or ongoing osteoporotic risk factors, necessitates treatment. However, the choices are limited and management is challenging for clinicians. This case series highlights the clinical conundrums in treating osteoporosis after bisphosphonate related subtrochanteric fractures. Clinical presentation: A 75 year old lady of South Asian origin was admitted with 3 week history of right thigh pain. Radiographs confirmed a partial subtrochanteric fracture with a similar (but less prominent) lesion on the left. Past medical history was hypothyroidism, bronchiectasis, breast cancer with previous radiotherapy, chronic kidney disease stage 4, secondary hyperparathyroidism and osteoporosis. Significant medications included alendronate for 9 years, lansoprazole, anastrozole for 16 years, and maintenance prednisolone. Both lesions were managed conservatively. She was osteoporotic with a 30% 10 year risk of major osteoporotic fractures but no treatment option was safe. Case Series Results: 9 female patients were reviewed (including the above case). Mean age at time of fracture was 77.3 (range 69-87) years. Eight had received alendronate and one had ibandronate. Mean duration of bisphosphonate treatment prior to fracture was 9.9 (range 3-16) years. Post-fracture, one patient with osteoporosis received teriparatide, while two others had contraindications to all treatment options and were monitored regularly. Active monitoring was also initiated for two patients with osteopenia and two with normal bone mineral density but ongoing risk factors. In total 5 patients had received radiotherapy for previous breast cancer, a contraindication to teriparatide. Learning Outcomes: Establishing reasons for original bisphosphonate prescription and periodically weighing benefits and risks of treatment is likely to help reduce the occurrence of these fractures. Following bisphosphonate related fractures, osteoporosis treatments are limited. Teriparatide, a bone forming agent, is the only choice but not suitable for all patients. Denosumab is contraindicated due to links with atypical femoral fractures. Selective oestrogen receptor modulators are ineffective for preventing nonvertebral fractures, and strontium ranelate is no longer available.
Discussion: Further research is needed and novel agents, especially those that safely promote bone formation, would be most welcome. Background: Bone stress injuries are typically overuse injuries associated with repetitive loading of bone and inadequate recovery. A continuum of bone stress injury from periosteal reaction to cortical fracture exists1, 2. Intrinsic and extrinsic recognised risk factors have been encapsulated within broader working consensus statements e.g. Relative Energy Deficiency in Sport (RED-S)1, 2, 3. Objectives: To assess current practice in management and outcomes of bony stress injuries presenting to a secondary care sports medicine service and develop a cross-specialty, trust-wide clinical pathway. Methods: This was a retrospective analysis of patient records (n=41) attending between February 2016 and December 2017. Patients were identified using initial consultation working diagnosis of a stress injury with subsequent MRI confirmation. Data analysis was performed using the RED-S consensus paper3. Results: 70.7% of patients were female. The commonest associated sport was running (61%). Stress injuries location included; tibia (51.2%), metatarsal 22%, femoral neck (9.8%), pelvic (4.9%). 22% were vitamin D deficient (<30 nmol/L) and 29% had levels >75mmol/L. Risk factors documented included training (76%), sleep (12%), diet (63%), menstrual (76%), mental health (17%) and gastrointestinal (5%). Discussion: Results demonstrate lower limb dominance of stress injuries, with running and dance featuring heavily which reflects this SEMS patient cohort. This data highlights the importance of clear documentation within patient notes of all risk factors to be addressed, identifies areas for improvement and raises the need to further consider optimal use of intra specialty referrals to streamline patient pathways given the current NHS environment and resource pressures. Conclusion: We have utilised the analysis to develop a trust-wide clinical pathway for bony stress injuries demonstrating the value of SEM within the NHS. Implementation of this will enable prospective data collection across specialties to ensure compliance with best evidence -thus improving healthcare resource utilisation and morbidity. Introduction: X-linked hypophosphataemia (XLH) is a renal phosphate wasting disorder and the most common form of heritable rickets. We report a case that illustrates some of the challenges in managing this disease. Clinical presentation: A 22 years old woman was diagnosed with XLH at the age of 2, after her parents noticed that her legs were bowing when she started walking. No other family members were affected. She followed regular treatment until 15 years old. She had multiple operations to correct leg deformities and a history of fracture at the right femur. Investigation: She had low 25OHD 15 nmol/L, high PTH 155ng/L, low serum calcium (sCa) 2.16 mmol/L and low urinary calcium (uCa) 0.8mmol/24 hr suggesting vitamin D deficiency. BMD showed osteoporosis at lumbar spine (T score -2.6) and total hip (Tscore -2.6). She reported low dietary calcium intake, use of Depo-provera and was a house bound smoker. Management: She was treated with high dose vitamin D (100,000 IU/m for 4 m) and calcium supplements. After one year, her BMD increased 9% at spine and 8% at the hip. Phosphorus (P) was low (0.49 mmol/L), sCa was normal (2.42 nmol/L), and alkaline phosphatase (ALP) was high (150 IU/L). After a foot operation treatment was started with calcitriol 1 to 4 mcg/d, as calcium remained normal. As P remained low, phosphate supplements (K-Sandoz) were added, and changed to Kphos to decrease stomach discomfort. PTH and uCa normalised but P remained low and ALP remained high. She reported good compliance. Calcitriol was progressively increased to 6 mcg/d and K-phos to 6 tablets/ d. Phosphorus levels remained low (0.53mmol/L) but ALP was normal.
P6 DEVELOPING A CROSS-SPECIALITY BONE STRESS INJURY CLINICAL PATHWAY
A genetic test confirmed a PHEX mutation (c.1979 G>A). Discussion: XLH treatment in children with calcitriol and phosphate supplementation is well established. The aim is not to normalise P but to reduce symptoms and surgeries and increases adult height. In adults, the treatment aims to reduce pain symptoms and osteomalacia and to improve fracture healing and surgical recovery. As in other chronic diseases, compliance is a big challenge. (6):1016-25) has shown that Prostate Cancer (PC) patients treated with oestradiol patch (OP) instead of luteinising hormone-releasing hormone agonist (LHRHa) therapy do not suffer loss of bone mineral density (BMD) but in fact have improved BMD. This is consistent with previous studies that have shown that oestradiol suppresses bone resorption and promotes bone deposition. In this study we measured biochemical bone turnover markers (BTM) to further investigate the mechanism of the observed BMD changes. Method: The resorption marker urine N-telopeptide (NTx) and formation marker serum total procollagen type-1 N-terminal peptide (P1NP) were measured using immunoassays in 9 OP and 9 LHRHa treated patients. Baseline, 1 and 2 year post-therapy samples were analysed and compared. Slope-values for changes in BTM were derived by Pearson regression and compared using MannWhitney U-test. Results: From baseline measurements there was an increase in P1NP (mean slope 26.2 μg/L year-1, SD = 31.3; n=9) and NTX (mean slope +12.0 nM/mM Cr year-1, SD = 17.8; n=7) in OP treated PC patients. In LHRHa patients there was a decrease in both P1NP (mean slope -39.6 μg/L year-1; SD = 76.0; n=9) and NTx (mean slope -24.5 μg/L year-1; SD = 36.6; n=9). Comparison of slope-values between the groups showed that the differences were statistically significant for both P1NP (p<0.005) and NTx (p<0.01). Conclusions: BTM were increased in OP treated patients, with a relatively higher increase in the formation marker suggesting a net increase in BMD. In LHRHa treated patients both markers decreased over the two-year study period. These findings are consistent with previously reported BMD differences between the two treatment groups. Assessment of bone markers could provide a sensitive and convenient method for monitoring hormone treated PC patients for changes in BMD and management of fracture-risk. Introduction: The aim of this study was to evaluate the effects of glucocorticoids (GCs) on trabecular and cortical bones at proximal femur using DXA-based 3D modeling. Methods: 402 men and women receiving GCs (≥5 mg/day, for ≥3 months, prednisone equivalent) were included in this study. They were randomly gender-, age-and BMI-matched with 1087 control subjects (1:2 to 1:3). Individuals were included in the control group if they had not received glucocorticoid therapy and if they had a Z-score within -2 to +2 at both spine and femur sites. GCs subjects were stratified depending on their fracture status. Areal BMD (aBMD) was measured at lumbar spine (aBMDLS), total femur (aBMDTot) and femoral neck (aBMDFN). A software algorithm was used to derive QCT-like subject-specific 3D models from the hip DXA scans of the participants and controls and compute the trabecular volumetric BMD (Trabecular vBMD) and the cortical surface BMD (Cortical sBMD). Results: GCs-treated patients had a significantly lower aBMDTot and aBMDFN (p<0.05) compared with controls without any difference at aBMDLS (p=0.72). Using 3D modeling, a significantly lower cortical sBMD (p=0.02) at total femur (TF) and trabecular vBMD (p=0.012) at neck were observed in GC-treated patients (Figure 1 ). When stratified based on their fracture status, GCs-treated patients with fracture had a significantly lower aBMDTot, cortical sBMD at TF, trabecular vBMD at both TF and neck than individuals without fracture (all p<0.05). Cortical sBMD has the strongest association with fracture events in the GCs group, as expressed by an odds ratio per SD decrease of 1.42 [1.08-1.87] and an AUC of 0.59 [0.54-0.64]. Conclusions: We observed an impairment of both cortical and trabecular compartments in GCs-treated patients, at total femur for the cortical bone and localized at the neck for the trabecular compartment. Presence of fracture is associated with a low cortical sBMD. Background: Persistence with osteoporosis therapies is essential to achieve optimal clinical outcomes. Objective: Estimate persistence with osteoporosis therapies in postmenopausal women treated in UK primary care practice. Methods: Data were obtained from the Clinical Practice Research Datalink for women aged ≥50 years (or aged <50 years with early menopause) who received at least one prescription for any osteoporosis therapy between 2010 and 2015. Persistence (the duration of time from treatment initiation to discontinuation) was estimated using Kaplan-Meier analysis at 6, 12, 18 and 24 months (primary objective) and at 36 and 60 months (exploratory objective) in three patient cohorts: 'All Patients' (persistence to any treatment), 'Naïve Patients' (no previous exposure to any osteoporosis medication) and 'Drug-specific' (persistence to specific treatments). Data were censored at patient death or loss to follow-up. Results: The 'All Patients' cohort comprised 72 256 women (46 924 treatment-naïve). Persistence with any therapy was higher in the 'Naïve Patients' than in the 'All Patients' cohort: 37.3% versus 31.0% at 24 months and 17.6% versus 13.1% at 60 months, respectively. The 'Drug-specific' cohort comprised 72 857 patients (46 390 treatmentnaïve; 44 039 non-treatment-naïve). At 24 months, persistence was higher with denosumab than with other therapies (50.0% for denosumab vs 19.0%, 15.2%, 12.9%, 6.9% and 0.0% for oral bisphosphonates, parenteral bisphosphonates, SERMs, strontium and PTH, respectively). A similar trend was seen at 60 months (Figure 1 ). Persistence with oral therapies was higher in treatment-naïve than in non-treatment-naïve patients, whereas persistence with parenteral therapies was higher in non-treatment-naïve than in treatment-naïve patients. Discussion: This study from 2010-2015 shows that persistence with osteoporosis therapies remains poor: 24-month persistence was 31%. There is a need to improve persistence, particularly in real-world practice. Conclusion: In this study, persistence was higher among patients receiving subcutaneous denosumab rather than oral or intravenous medications.
P9 CHANGES IN BONE TURNOVER MARKERS IN ADVANCED PROSTATE CANCER PATIENTS TREATED WITH LHRH AGONISTS AND TRANSDERMAL OESTRADIOL PATCHES
P10 EFFECTS OF LOW DAILY DOSE OF GLUCOCRTICOIDS ON TRABECULAR AND CORTICAL BONES AT THE FEMUR
P12 A RAPID AND EFFECTIVE REGIMEN FOR TREATING VITAMIN D DEFICIENCY IN OLDER PEOPLE
Aza Abdulla, Nan Ma, Adam Garland Department of Clinical Gerontology, Kings College Hospital NHS Trust, Princess Royal University Hospital, Orpington, UK Background: Vitamin D (vitD) deficiency is a common population-wide problem, which if managed effectively will reduce morbidity from osteoporotic fractures and potentially improve QoL. A variety of regimens are employed for treatment. Most are empirical recommendations based on historic practices rather than clinical evidence. The recent NICE guidelines [2016] are similarly based on available literature and recommendations from commissioning groups and local guidance from hospitals and regional prescribing committees. Most recommend weekly loading regimen for 6 to 8 weeks limiting the cumulative dose of VitD to 300,000 IU. This, in our view, is significant time-spend for older people but also insufficient to replenish vitD stores. In contrast, our practice has been short intensive course of vitD over 2 or 3 weeks, given daily as 50,000 IU ergocalciferol orally. Objective: Evaluate our practice through a quality improvement project to determine its effectiveness before deciding to implement change in line with NICE guidelines. Methods: In the initial study, patients with low vitD (< 80 nmol/L) received a 2-week course of daily ergocalciferol (50,000 IU) followed by maintenance with vitD 800 IU/day. Patients with CKD stage 4 were excluded. Tests were repeated within 4 weeks after completion to check adequacy of treatment. In a follow-up study, we extended treatment to 3 weeks for severe deficiency (<20nmol/L). Results: In the initial study, 42 patients (mean age 82 years, 72% female) were included. Median pre-treatment serum 25(OH)D was 30.7 nmol/L (range 8 -67) which increased to 91.7 nmol/L (40 -175) following treatment. We noted that patients with severe deficiency (<20nmol/L) a two-week course was insufficient to adequately replenish depleted stores. In the follow-up study, 34 patients were included (mean age 82.9 years). After 3 weeks, all (100%) patients achieved vitD levels above deficiency (>40nmol/L), and 71% had normal levels. No side effects were reported and none reached toxic vitD levels. Conclusion: The current guideline recommendations are below the dosage needed to treat vitD deficiency especially severe cases (25(OH)D< 20 nmol/L). As per our practice, VitD is safe and can be administered as a short intensive course over 2 to 3 weeks. In contrast to current guidance of slow replacement, this short intensive therapy should also improve compliance. Although rare, Atypical Femoral Fractures (AFF) are a concern for both patients and healthcare professionals. Currently the MHRA recommend patients on bone sparing therapy report any thigh, hip or groin pain. A key part for an effective fracture liaison service is monitoring patients for adherence and tolerance to bone therapy. The impact of adding a question on thigh pain to the monitoring assessment is not known. Objective: To determine the number of patients report thigh pain as part of their monitoring form and their subsequent clinical management. Method: A question on new thigh pain since starting oral bisphosphonate medication was added to the standard FLS four and twelve months monitoring patient completed questionnaire. If the patient reported any thigh pain a standard letter was sent to the patient and copied to the GP. The letter recommended the patient see the GP to decide if an x-ray was required. All completed monitoring assessments between 1.1.2018 and 31.3.2018 were included. We then used our local radiology database to see how many patients had a subsequent femoral x-ray. Results: 140 forms were returned and the information on the first 32 are presented here. 23 were female and 8 had a hip fracture. Overall, 68.8% reported any new thigh pain. Of these, only 18.18% patients had any subsequent radiology of the femur. The rate of thigh pain was 75% in those with a hip fracture and 66.7% in patient with other fractures. Conclusion: Adding a question about new thigh pain resulted in a significant increase in workload for the FLS, with few patients then having appropriate imaging as per recommendations to primary care. Discussion: Given the rarity of AFF, the value of adding a question about thigh pain within the FLS setting is questionable. Background: A hospital-wide electronic alert was introduced due to the increased hospital zoledronate (ZOL) prescribing and expansion of community osteoporosis teams to facilitate data sharing of patients between primary and secondary care. Patients would have an alert created on the trust's patient administration system following ZOL administration. All clinicians in secondary care and the community osteoporosis team have access to this system with different 'read/write' privileges. Objective: An audit of ZOL administration practice was done using this database. Methods: Data was analysed on inpatients administered ZOL from 1/9/ 2017 -28/2/2018. Patients under Trauma & Orthopaedics were excluded.
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As part of this audit, standard for ZOL administration (standard = 100%) included: ZOL indication documented; blood tests (calcium, renal function, vitamin D) completed; creatinine clearance (CrCl) calculated; and information on ZOL administration and subsequent infusion plan documented in hospital discharge summaries. Results: 57patients (61% female, mean(SD) age 82.5(7.3)years) had ZOL administered in this period. ZOL was administered a median 6days (range 0-58days) into their inpatient stay. 32patients (56%) had an existing diagnosis of osteoporosis; with 27patients (84%) on treatment already.
ZOL was administered in patients with low calcium (<2.20mmol/L), 4patients; low 25-OHD (<35nmol/L), 11patients; and low CrCl (<35ml/ min), 2patients. There were no adverse effects that were directly attributed to the infusion. Discussion/Conclusion: This audit has highlighted that there is suboptimal safety check pre-ZOL infusion and that information is not routinely translated to primary care. The introduction of a hospital-wide electronic alert allows creation of a database to monitor patient safety when ZOL is administered for osteoporosis.
P15 HOW THE FRACTURE LIAISON DATABASE (FLS-DB) IMPROVES PATIENT CARE Ann Hunt
Falls and Fracture Liaison Service, Suffolk GP Federation, Bury St Edmunds, UK The community FLS run by 2 WTE nurses covers 25 practices, population 107,053 (50yrs+), in a semi-rural area. The aim is to systematically identify, assess, treat and refer patients over 50yrs to appropriate services reducing future risk of falls and fractures. Using information technology was the most efficient way to case find. The team proactively case finds appropriate patients by triaging a monthly spreadsheet prepared by the hospital coding department highlighting all fractures in patients over 50yrs. 71 % of patients on list are appropriate for FLS assessment. Patients are also highlighted from DXA reports. Patients are assessed 4 and 12 monthly post fracture, regarding compliance with treatment and further falls or fractures. Falls assessments and referral for exercise are 24.77% above average. The FLS-DB has helped to focus service development by identifying gaps in the service. Using the database has shown our case finding method is 6.1% above the national average and for vertebral fractures we identify 2% above average. Follow ups at both 4 and 12 months are 47.93% and 55.65% above average respectively. The Background: Evidence supports the use of bone turnover markers (BTMs), in particular the geometric mean of a healthy premenopausal reference interval (threshold), to monitor response to osteoporosis treatment. A greater than 90% sensitivity in showing response of women to oral bisphosphonate treatment has been demonstrated in a trial setting. Adherence with intravenous zoledronate therapy is excellent, therefore is there any point in measuring bone turnover markers to identify nonresponders? Objectives: To establish the diagnostic accuracy of PINP and OC set at threshold with two different assays, to show response of clinical patients to zoledronate therapy. Methods: A cohort of 100 unselected patients from a single metabolic bone centre (24 male; 76 female), receiving 5mg annual zoledronate for osteoporosis, were recruited after at least one previous infusion. From a single serum sample, we measured N-MID osteocalcin and Intact and Total PINP using the IDS-iSYS and Roche Cobas e411 respectively. Clinical DXA data were collected from within one year of commencing treatment and a follow up 1-3 years later. Results: The cohort receiving zoledronate, with a mean age of 70 years and mean T-score of the total hip of -1.75, demonstrated good suppression of all the BTMs with each assay as shown in Table 1 . This only conferred a positive difference in mean percentage change in BMD for the IDS OC assay. Discussion: The sensitivity of the BTMs in a clinical unselected cohort at the threshold target are equivalent to a study population. There is no difference between assays. We had limited data on BMD and the response rate was very high and so there were few subjects with BMD in the control group. Conclusion: The diagnostic accuracy for treatment response to zoledronate for PINP and OC using two different assay manufacturers was similar and the response rate was high; non-response was associated with reduced hip BMD change. We describe the clinical and radiological features of all cases of suspected AFF, seen within a supra-regional referral centre between 2007 and 2017. Clinical presentation: We identified 72 (8 male) definite (n=51), possible (n=14) or unlikely (7) adult cases suspected of AFF, of mean (range) age 68 (39-91) years, most (n=63) associated with oral or parenteral bisphosphonates for 8.9(2-21) years, usually for osteoporosis. Other indications were Paget's disease (n=1), osteogenesis imperfecta (n=3), bone marrow oedema syndrome (n=1), lumbago (n=1), and osteitis (n=1). 12 patients had significant steroid exposure. First AFF were equally split between left and right femurs, occurred anywhere between the lesser trochanter and supracondylar flare, and were bilateral (with high degrees of symmetry) in 34 (52%) patients. 47 (75%) patients presented with at least one completed fracture, often without trauma. Investigation: Fractures were diagnosed on plain radiographs, scintigraphy, MR or CT. Patients with AFF without prior bisphosphonate exposure (n=6) had higher bone mineral density (mean femoral neck T score -0.62 versus -1.78, p 0.030). Mean (SD) serum alkaline phosphatase was 89 (31) U/l, excluding one patient with adult hypophosphatasia. Management: Complete fractures were either orthopaedically nailed or plated, and incomplete fractures nailed prophylactically, treated with teriparatide or observed. In all cases where the diagnosis of AFF was diagnosed prospectively the bisphosphonate was withdrawn. Sequential imaging showed healing, or progression of periosteal elevation in individual patients. PTH therapy helped 4/11 patients, but one still progressed to complete fracture during therapy. Discussion: AFF are important and easily overlooked on initial screening radiographs. A high degree of clinical suspicion is required during long-term bisphosphonate treatment, and careful radiologic scrutiny. Our data confirm in a few cases the natural history of progression from periosteal reaction to complete fracture over many months, often accompanied by prodromal symptoms. Their frequent symmetry suggests strong mechanical influences determining site and severity of fractures. Optimal management remains unclear. Background: Data from the FREEDOM trial show that denosumab increases bone mineral density (BMD) and reduces the incidence of fractures in treatment-naïve post-menopausal women with osteoporosis. In a real-life setting, most patients would have had previous treatment with bisphosphonates and it is not clear whether this has an impact on treatment response. Denosumab can be used in patients who have osteoporosis and chronic kidney disease (CKD). However, it is not known whether renal impairment influences the effect of denosumab on BMD. Objective: The aim was to investigate changes in BMD following denosumab in patients who (1) Postmenopausal osteoporosis is characterised by increased bone turnover and an imbalance between bone resorption and formation. Bisphosphonate treatment reduces bone turnover but their effect on bone balance is yet to be fully investigated. Using the T-score approach our aims were to: i) investigate the effects of oral nitrogen-containing bisphosphonates on bone balance and turnover in postmenopausal women with osteoporosis and ii) determine the relationship of the change in bone balance and turnover with the change in BMD at the lumbar spine and total hip Women were recruited, mean age 67years, and randomised to receive: ibandronate (n=55, 150mg/month), alendronate (n=54, 70mg/week) or risedronate (n=56, 35mg/week). They also received calcium and vitamin D daily. A fasting serum sample was collected at baseline and weeks 1,2,4,12,13, 48 and 96. The control group were 226 healthy premenopausal women receiving no treatments. PINP and CTX were measured using the iSYS-IDS analyser and BMD (in g/cm2) of the lumbar spine and total hip were measured by DXA (Hologic Inc). PINP and CTX values were log 10 -transformed and normalised. T-scores were calculated for using the mean and standard deviation from the premenopausal group. Bone turnover and bone balance were calculated from the T-scores. Mean levels (95% CI) of balance and turnover are shown in the table. The change in turnover at weeks 4, 12 and 48 was inversely correlated with the change in lumbar spine and total hip BMD at weeks 48 and 96, (p<0.01 to p<0.001). The change in balance at week 4 positively correlated with the change in total hip BMD at weeks 48, (p<0.01). Bisphosphonates resulted in an initial positive balance and a reduction in turnover. Some of these changes were associated with increases in BMD. Bone turnover is a better predictor of BMD than bone balance. Background: People living in residential care have a greater risk of osteoporosis and fracture than community dwelling older adults and warrant intervention to improve bone health and muscle strength. Objective: To investigate differences in factors related to bone health in individuals from residential care facilities and from the community admitted following a hip fracture and to investigate how these factors relate to length of stay. Methodology: An audit of all patients admitted with hip fracture to one UK unit in a 12 month period was conducted. Mann-Whitney U & chisquare for independence analysis compared characteristics between those in residential care with community dwellers. Spearman rank correlation was used to compare relationships between variables. Results: Those in residential care (n=51) made up 14.4% of total admissions to the unit (n=352). Individuals from residential care were significantly older than community dwellers (median; interquartile range; 86.0; 11.0 vs. 81.0; 12.0 years, P=0.0001) and had significantly lower haemoglobin concentration on admission to the unit (118.0; 22.0 vs. 125.0; 21.0 g/L, P=0.0001). There was no significant difference in the frequency of bisphosphonate use (P=0.286), calcium/vitamin D supplement use (P=0.992), serum urea (7.3; 3.0 vs. 7.2; 4.4 mmol/L, P=0.147), or creatinine (78.0; 35.0 vs. 75.0; 38.0 μmol/L, P=0.436) between the groups. Residential care dwellers spent more time pre-operatively, postoperatively and in total in hospital, but numbers were too small to achieve statistical significance. A significant positive correlation was observed between urea and creatinine and total length of stay (r=0.225, P=0.001; r=0.193, P=0.007; respectively) and post-operative days (r=0.224, P=0.002; r=0.214, P=0.003; respectively). A significant negative correlation was observed between haemoglobin and total length of stay (r=-0.202, P=0.004) and post-operative days (r=-0.206, P=0.004). Discussion: Patients admitted from residential care were older and more anaemic than community dwellers, and an association between anaemia, renal impairment and length of stay was observed. Non-significant trends were observed towards greater time pre-and post-operatively in residential care dwellers, which might be important in a larger sample. Conclusion: The study highlights differences in residential and community dwellers admitted with hip fracture, and provides useful data for both care interventions and further investigations. Background: A patient survey led us to design, develop and evaluate combined information and physical activity sessions for patients at high risk of fragility fractures. Objective: To encourage effective self-management. Intervention: 6 x 60 minute (split between information and activity) weekly combined programme -information covering osteoporosis, fracture risk, treatments, nutrition, and benefits of exercise (CNS and OT). -activity 12-station individually tailored activity circuit, practiced strength/ balance exercises, Tai Chi, Pilates, relaxation and getting up after a fall (physiotherapy-led). 6-10 participants each group. Completed questionnaires weeks 1, 6 and at later Group review (October 2017). Results: 61 (59 female) patients (mean age 69, range 55-89) -7 courses. 51/61: previous fragility fracture (28 spine, 3 hip). Course completion: 81%, no reported injuries/participant satisfaction high. Group Review (37/61) 5-22 months after course completion. Questionnaire results Circle the number (0-10) that indicates how much/well you know about osteoporosis and your individual risk of breaking bones (fractures) (Before course: average 5.6, after course 8.2, at review 8.1), you understand your bone density scan results (4.9, 7.2, 6.9), you know about the way the treatments you have been prescribed work (5.0, 7.9, 7.9), you know about the types of food which would be good to include in your diet (6.0, 8.7, 8.6) , you know about the type/amount of exercise you can do to help your bones (5.0, 8.4, 8.4) , you think taking part in regular exercise would help your bones and reduce your level of pain (7.4, 9.2, 8.8), how confident you would feel about joining a local exercise class (6.9, 8.7, 7.2). Discussion: Participants retained improved personal knowledge of osteoporosis diagnosis, treatment, diet and exercise (mean improvement: 46% to 8/10) However, confidence taking part in exercise fell -average 17% between course & review. Conclusion: An information and activity intervention for patients at high risk of fragility fracture is safe, accepted by participants and allows retention of knowledge around self-management. However, a strategy to maintain patient confidence in their ability to exercise is required and now a focus. Objective: To examine the effect of exercise interventions (high and/or low force resistance, and impact exercise) on BMD of the wrist and forearm, using published data. Methods: A structured and comprehensive search of databases (including MEDLINE, EMBASE, CINAHL, PEDro, Web of Science, Controlled Clinical Trials and AMED) was undertaken to locate relevant studies published and unpublished up to June 2017. Titles, abstracts and full texts articles were independently screened against pre-specified eligibility criteria, by pairs of reviewers. Data extraction was carried out using a customised and piloted data extraction tool. Included studies were quality appraised using the Cochrane risk of bias tool. Random effects meta-analysis of the percentage change in distal radius BMD from baseline was conducted. A narrative synthesis was conducted to summarise characteristics of the exercise interventions. Results: 2180 unique citations were screened, 165 studies reviewed for full-text eligibility, and 28 studies were included in the review, of which 24 provided suitable data for meta-analysis. Study quality ranged mostly from low to unclear risk of bias across risk assessment domains. Exercise generally led to moderate increases in distal radius BMD (SMD =1.37, 95% confidence interval (CI) =0.75, 1.98, overall effect Z value =4.36, p<0.001). Subgroup analysis based on menopausal status showed postmenopausal women were more likely to benefit from upper body exercise interventions (SMD =1.88, 95% CI =1.10, 2.66, Z value =4.74, p<0.001) than premenopausal women. Conclusion: There is some evidence from existing data to support the role of exercise in increasing BMD of the wrist and forearm. However, there is wide heterogeneity in the available data. As such, mode, frequency and type of exercise required to effectively increase BMD at the wrist and forearm should be explored in future research. Smoking is an important risk factor for fracture as it suppresses osteoblastic activity. Patients at high risk of fracture should be given smoking cessation advice as part of a package of lifestyle management/advice. Previous research in smoking cessation generally shows that advice from doctors, structured interventions from nurses, and individual and group counselling are effective interventions to promote smoking cessation. However, it is unknown how patients with a fragility fracture respond to advice to stop smoking in the context of Fracture Liaison Services (FLSs). Objective: To determine the proportion of smokers who self-reported smoking cessation at 3 month review, when given smoking cessation advice in FLS. Methods: All patients who reported smoking attending FLS between 01/ 09/2017 and 31/12/2017 were given smoking cessation advice and asked in their subsequent 3 month telephone follow-up review if they had managed to give up smoking. Patient demographics and self-reported smoking status were recorded. Results were analysed using descriptive statistics and percentages. Results: In the observation period 600 patients were seen in total in FLS. 211(35.1%) patients received treatment recommendations, and required follow-up, 20 (9.4%) were smokers. Of the smokers, 12(60%) were female and 8(40%) were male and the mean age was 65. At their 3 month review, 3 (12%) self-reported smoking cessation. Discussion: These results suggest, albeit a small proportion, advice to stop smoking may be effective in the context of FLS. Limitations of this small audit include the small numbers, self-reported smoking status, the lack of information on patients' motivation to stop (i.e. whether the FLS encounter was an important motivator or catalyst in the decision to stop). Conclusion: Although relatively few patients attending FLS smoke, these findings suggest that attending FLS may be a trigger to stop smoking in a small percentage. Further questions remain about the impact of FLS lifestyle advice on other health behaviours e.g. reducing alcohol consumption and adoption of weight bearing exercise. The FLS community could engage with specialists in other areas to share best practice in promoting lifestyle change. Background: Physical activity during adolescence is known to be beneficial for bones and affect bone mineral accrual. The use of muscle action during physical activity plays a major role in the development of the skeleton. We have previously reported the association of bone outcomes with muscle strength. Objective: The aim of this study was to determine if self-reported physical activity per se influenced bone volumetric density (BMD) and geometry parameters in the appendicular peripheral skeleton of young adult males (YM). Method: 114 YM were recruited to this cross-sectional study after fulfilling the inclusion criteria: European Caucasian, aged 18-24 years, in good general health, not taking medication known to affect bone and/or muscle, no reported fractures in past year and able to give informed consent. Physical activity was quantified in hours per week using a lifestyle questionnaire. Peripheral quantitative computed tomography (pQCT) measurements were taken at the 4% and 50% radius and 65% tibia sites. Measurements included: 4% radius total bone area (TBA), trabecular and total BMD. At the radius and tibia 50% and 65% sites respectively: total bone area, radial/tibial TBA, medullary area, cortical bone mineral content, cortical BMD, cortical area, cortical thickness, and, measures of strength -moment of inertia, stress strain index. Stepwise regression was performed to determine influence of physical activity upon all bone parameters; covariates including age, height, weight. Results: Physical activity undertaken was significantly related to total bone area of the radius p=0.04. Amount of physical activity was not significantly related to any other bone parameters in the radius and tibia in YM. Discussion and conclusion: With the exception of bone area, selfreported physical activity was not associated with bone outcomes at the peripheral skeleton. Given our previous findings of strong associations with muscle strength and bone this result highlights the importance of measuring muscle strength directly rather than using self-reported physical activity. Background: Systematic reviews and meta-analyses have demonstrated that exercise is an effective intervention to prevent falls in older adults living in the community. However, there remains uncertainty about the safety of prescribing exercise in this group, particularly considering many may have underlying osteoporosis. Objectives: To update the review on the effect of exercise on falls by Sherrington et al (2017) and to extract additional data on adverse events and drop outs. Methods: The review by Sherrington was updated to include papers published up to 2017 using the same search techniques and inclusion criteria. Meta-analysis was performed to determine the pooled effect of exercise on fall risk as well as the rates of drop outs and adverse events between trial arms. Results: 94 comparisons from for 81 trials were available for meta-analysis. Exercise reduced the falls rates in community-dwelling participants (pooled rate ratio 0.79, 95% CI 0.74 -0.85, p<0.001, I
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2 46.3%, 85 comparisons).Where data for adverse events (AEs) were reported in all trial arms, intervention participants reported greater overall AEs than controls (pooled rate ratio 1.08, 95% CI 1.04 -1.13, I 2 97.8%, 8 comparisons). Intervention related AEs (IAEs) included falls, muscle stiffness and pain. Fractures were rarely reported as IAEs. Intervention participants were more likely to drop out of before trial completion (pooled rate ratio 1.10 95% CI 1.01-1.19, I 2
45.7%, 83 comparisons).
Discussion: Exercise appears to be associated with an increased likelihood of musculoskeletal pain and discomfort in older adults living in the community but there is no increased risk of falls or fractures. In fact, the overall effect of exercise is to reduce the risk of falls. A greater proportion of older adults drop-out from trials when allocated to an exercise arm. This suggests that although exercise is safe and effective, albeit sometimes uncomfortable; more work is required to improve acceptability. Few trials included structured reporting of AE's in all trial arms. Sherrington, et al. Exercise to Prevent Falls in Older Adults: An Updated Systematic Review and Meta-Analysis', Br J Sports Med,51(2017), 1750-58. Background: There is an urgent need for large scale research to identify modifiable risk factors associated with low bone mineral density (BMD) in ethnic minority groups; research to date has been very limited. Objective: In this study we investigate the association between BMD, as estimated from heel bone ultrasound attenuation (BUA; Sahara Heel Ultrasound, Hologic, USA) and dietary, lifestyle and anthropometric factors in UK South Asians. Methods: The UK Biobank is a large, ongoing UK-wide cohort with data on >500,000 individuals, aged 40-69 years, recruited from 2006-2010. Our analysis uses data from n 2438 South Asians (n 1079 females, n 1359 males; n 114 Bangladeshi, n 1625 Indian and n 699 Pakistani) who had a baseline heel BUA measurement. Mean (+/-SD) for age was 53+/-8 years and for Body Mass Index (BMI) was 27(5) kg/m2.
P26 B O N E H E A LT H A N D D I E TA R Y, L I F E S T Y L E & ANTHROPOMETRIC FACTORS IN URBAN DWELLING SOUTH ASIANS (n 2438
Results: Partial correlations, adjusted for age, or chi-square tests (as appropriate) were undertaken to assess the association between heel BMD and a range of anthropometric and demographic variables. A Bonferroni adjusted P value cut-off for statistical significance of P<0.002 was used (n=33 tests). For brevity, only statistically significant results are reported here. In females, there was a positive partial correlation between gross household income and heel BMD (r=0.17 P<0.001 n 752). In males, there was a positive partial correlation between BMI and heel BMD, (r=0.07 P<0.001 n 1349). Discussion and Conclusion: Our results suggest that having a lower income (females) or a lower BMI (males), are associated with lower heel BMD. Western dwelling South Asians with these particular characteristics may benefit from public health interventions to improve bone health. This is the first analysis to date assessing the association between heel BUA, dietary, lifestyle and anthropometric factors in a large UK South Asian cohort. We are now conducting further work using more clinically relevant measures of bone health (e.g. hip, wrist and spine BMD) in this cohort. This research has been conducted using the UK Biobank Resource under application number 15168. Brief, high impact exercise increased femoral neck bone mineral density (BMD) in premenopausal women and older men. The aim of this study was to investigate if high impact exercise is feasible and effective in increasing BMD in postmenopausal women. Participants were healthy post-menopausal women aged 55-70 y. The six month intervention involved high impact unilateral (hopping) exercise on one randomly selected leg. The first eleven weeks of the intervention were progressive whilst all women were asked to complete 50 multidirectional hops each day in the final 15 weeks. BMD was measured for both femora using DXA pre and post intervention. Participants completed a diary detailing the number of hops completed each day, any pain or discomfort and any reasons they couldn't exercise. Repeated measures ANOVA was used to detect any significant difference in response between legs (leg*time interaction). Thirty-six women (age 61.0±4.2years; BMI 23.9 ±3.5kg/m2) were recruited. Three participants were lost to follow up and four withdrew prior to week 11 (knee pain n=3; Achilles tendinopathy n=1). The remaining participants completed 74.8 ±22.9% of prescribed sessions in the final 15 weeks. Intention to treat analysis showed no significant difference in response between legs (P=0.060). In the 24 participants who exercised at least 4 times per week, femoral neck BMD increased significantly in the exercise leg (+0.4%) relative to the control leg (-1.1%; P=0.026). Participants reported 2.5±1.5 occasions of pain or discomfort during the intervention. Seven participants reported episodes that prevented exercise for over a week before resuming but only one injury (Achilles tendinopathy) persisted on cessation of exercise. The majority of postmenopausal women who started the intervention (69%) exercised at least four times per week, and high impact exercise improved femoral neck BMD. The adherence was a little lower, and incidence of exercise related pain or discomfort a little higher than in previous studies in younger women and older men. Whilst this type of exercise may be effective and feasible for the majority, the intervention may need modification for some postmenopausal women.
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P28 -Abstract withdrawn NEW EXERCISE DEVICE PROVIDES HIGH COMPRESSION FORCES WITH LOW INJURY RISK ON BONE RESULTING IN OSTEOBLASTIC ACTIVITY
Jason Conviser, Jenny Conviser Physical Science, Ascend -Consultation in Health Care, Chicago, Illinois, USA Introduction: The relationship between bone geometry and mechanical influences on bone suggests that when significant forces are applied to bone, the compression will stimulate an adaptive response (Wolff's Law).Exercise is recommended as a treatment option for those diagnosed with osteoporosis. However, traditional exercise does not create the forces needed to stimulate bone growth in a safe and effective manner. A novel apparatus that allows for significant compressive force to the level required to have an effect on the osteoblastic function offers high force production with short duration, i.e. osteogenic loading (OL) was utilized. OL has been suggested as a non-pharmaceutical option to improve bone health. Objective: The purpose of this study was to examine if OL was 1) safe and 2) effective for individuals dealing with osteoporosis. Methods: Fifteen women ranging in age from 56-84 years from three independent clinical locations with a diagnosis of osteoporosis were selected to participate in a one-year study using a new exercise device that allows the individual to create significant forces on the bone with four unique exercise movements. All three centers had the same equipment, settings and protocol. Subjects completed a minimum of 48 sessions once a week over the year, each session lasting approximately 15 minutes. DEXA scans were conducted at the same testing location for both preand post-assessments. Subjects self-reported their body weight, weekly minutes of traditional exercise, diet and prescription medications. Results: Of the 15 subjects, 10 individuals demonstrated a significant reduction (improvement in bone) in their mean DEXA score, 3 had no significant change and 2 individuals showed a further degradation in their bone density. Within the 4 movements (chest press, leg press, abdominal crunch and vertical lift), forces generated were 2x -10x body weight with no injuries reported with any subject. These data suggest that a nonpharmacologic exercise solution is available to individuals diagnosed with osteoporosis. Further study is required with larger sample sizes and greater demographics. Additional research is needed to validate OL as a viable and safe strategy for bone reformation. School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK Background: Prolonged sitting (or sedentary behaviour (SB)) has profound detrimental effects on health and is associated with increased risk of chronic disease, hospitalisation and premature death. In clinical practice, one of the principle aims in the rehabilitation of older adults is to maintain or increase physical activity. However while in hospital, a person will spend the vast majority of the day sitting or lying down, often in a single uninterrupted bout. A number of strategies (including the popular twitter-based campaign #endpjparalysis) have started to be implemented in hospital wards to get patients up and moving. Objective: This is the first explorative study that measured objectively the postural SB of older hospitalised adults taking part in such initiatives. Methods: Forty-three people (mean age 83.8y (SD 8.3)) who were admitted at Kello Hospital (NHS Lanarkshire) wore a waterproofed activity monitor (activPAL3) on the front of the thigh for 4days (including overnight); SB was analysed for waking hours (defined as 6:00-23:00), for each day. Interventions designed to get patients up and moving were introduced sequentially (following a service improvement methodology), with each intervention including all elements from former ones. Participants were grouped based on the highest level of intervention they received. Results: There were 4 groups: 'control' (n=12), 'education' (advice of SB reduction via infographics on the ward noticeboards, n=12), '#endpjparalysis', (up and dressed by the nurses before 11:30am, n=9), 'personalised activity care plans' (custom-made advice by OTs on SB reduction, n=10). There were no differences between the groups (ANOVA) for total sitting time (p 0.989), time spent upright (standing and walking) (p 0.700), number of sitting events (i.e. sit to stand transitions) (p 0.418) and longest upright period (p0.915). Discussion/Conclusion: This small explorative study of hospital based patients identified the inability of current initiatives to decrease SB. The cross-sectional nature of the study limited the ability to assess change in individuals as interventions were introduced. Further work is warranted to untangle the determinants of SB in hospital settings and implement interventions of sustainable SB change in this setting. Background: We analysed hospital admissions and bed occupancy for fragility fractures in Ireland over a 15 year period to assess fracture admission trends and to project admissions over the next 3 decades. Methods: We used the Hospital In-Patient Enquiry Scheme (HIPE) to extract data on fracture admissions to Irish Hospitals between 2000 and 2014 inclusive. We calculated absolute numbers and age-standardised rates of hospitalisations for men and women ≥50 years for each osteoporotic-type fracture. We projected fracture numbers and bed days using these trends, and associated costs to 2046 based on 2014 rates. Results: The absolute number of all fragility fracture admissions increased by 30% between 2000 and 2014, for both men (40%) and women (27%). In-patient bed days for osteoporotic fractures have increased by 51% in the same period. Hip fractures dominated admissions, accounting for 36.5% of all admissions and almost half (46.7%) of all bed days. Age standardised rates of hip fracture admission decreased significantly (p<0.001) in women, but not in men, whilst rates of non-hip osteoporotic fracture admissions have not changed significantly for men or women. Hospitalisations for all osteoporotic fractures are projected to increase by 150% to 31,605 in 2046, 58% of whom will be 80 years of age or older. Discussion: There has been a significant increase in the number of fracture admissions in Irish men and women over the past 15 years. This is projected to increase further over the next 3 decades which will place a significant burden on the Irish healthcare system.
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P31 INCREASED RISK OF SELF-HARM IN PATIENTS WITH OSTEOPOROSIS: A UK POPULATION STUDY
James Prior, Rebecca Whittle, Alyshah Abdul-Sultan, Carolyn ChewGraham, Athula Sumathipala, Tom Sheperd, Christian Mallen, Zoe Paskins Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK Background: Prevention of self-harm, as a key risk factor for suicide, is an international public health priority. The World Health Organization recommends that clinicians should assess the potential for self-harm in patients in high-risk groups e.g. those with chronic pain and depression. Osteoporosis is associated with chronic pain and depression, but the risk of self-harm in osteoporosis has not previously been examined. Objective: To examine the risk of self-harm in patients with osteoporosis. Methods: We conducted a retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD). Our osteoporosis cohort was defined as those patients with either i) a Read code for osteoporosis or ii) a vertebral fracture Read code and aged ≥50 years. This cohort were identified between 01/01/1990-31/12/2016 and matched to controls without osteoporosis of the same gender and within the same 10-year age category. Incident self-harm was identified by a Read code after the diagnosis of osteoporosis. Characteristics of the sample were initially described and hazard ratios (HR) were obtained from cox-regression analysis to examine the risk of self-harm in patients with osteoporosis compared to matched controls. Analysis was initially unadjusted and then adjusted for age, gender, body mass index, smoking, alcohol, anxiety and depression. Results: Over the 16-year time-period, 126,316 patients had osteoporosis. These had a mean age of 70.3 years and 84.5% were female. Incidence rates of self-harm in patients with osteoporosis and matched controls were 8.0 and 4.8 per 10,000 person-years respectively. Unadjusted HR (95% confidence interval) for patients with osteoporosis compared to matched controls were 1.67 (1.48-1.88), which decreased when adjusted to 1.46 (1.28, 1.66). Discussion: Patients with osteoporosis in primary care are at almost 50% greater risk of self-harming compared to matched controls. Conclusion: Though self-harm in patients with osteoporosis is rare, this group of patients is at greater risk than other matched primary care patients and clinicians need to be aware of the potential for self-harm in this group. Background: Osteoporosis and fractures cause significant morbidity, mortality and considerable socioeconomic burden in the aging population. Cataract is the leading cause of blindness and visual impairment in the elderly. Objective: To evaluate the association between cataract and the risks of osteoporosis and fracture, and the effects of cataract surgery on osteoporosis and fracture risks. Methods: We conducted a nationwide population-based retrospective cohort study using the Taiwan's National Health Insurance Research Database. In total, 57972 cataract patients and 57972 healthy controls were included after 1:1 matching for age, sex, and index year. Incidences and hazard ratios (HR) for risks of developing osteoporosis and fracture were calculated using Cox proportional hazard regression models. Results: During the mean follow-up time of 6.3 years, 19189 patients developed osteoporosis or fractures in the cataract cohort, and 13803 in the non-cataract cohort. The diagnosis of cataract was significantly associated with an increased risk of developing osteoporosis or fracture (adjusted HR [aHR] = 1.37, p <0.001). In the analyses for each individual event, diagnosis of cataract was significantly associated with increase in all outcomes, including osteoporosis (aHR = 1.44, p <0.001), hip fracture (aHR = 1.16, p <0.001), vertebral fracture (aHR = 1.36, p <0.001), and other fractures (aHR = 1.26, p <0.001). In the cataract cohort, patients who underwent cataract surgery had significantly lower risk of developing osteoporosis or fracture (aHR = 0.55, p <0.001), compared to those without surgery. Moreover, undergoing cataract surgery was also associated with reduced risks of all individual events, including osteoporosis, hip fracture, vertebral fracture, and other fractures. Discussion: The strength of this study was its nationwide populationbased design, which provided a large sample size and long-term followup period. In addition, this study is the first to clearly demonstrate the association between cataract, cataract surgery, and occurrence of osteoporosis, and is one of the few studies evaluating the influence of cataract surgery on fracture risks. Conclusion: Cataract was independently associated with increased risks of osteoporosis and fracture. Among cataract patients, a potentially beneficial effect of cataract surgery on reducing osteoporosis and fracture risks was observed. Background: Post-stroke osteoporosis and consequent fracture increase the risk of morbidity and mortality and cause considerable socioeconomic burden. Objective: To investigate the association between statin use and risks of osteoporosis and fracture in stroke patients. Methods: We conducted a population-based propensity score-matched retrospective cohort study of patients newly diagnosed with stroke between 2000 and 2012 using the Longitudinal Health Insurance Database, a subset of the Taiwan's National Health Insurance Research Database. We analyzed 5254 propensity score-matched patients, including 2627 patients in the statin and non-statin cohorts, respectively. Cox proportional hazards regression models were used to calculate hazard ratios (HRs) for post-stroke osteoporosis, hip fracture, and vertebral fracture (together, the primary outcome) according to statin use status. Results: During the mean follow-up period of 4.2 years, 390 patients in the statin cohort and 535 in the non-statin cohort developed the primary outcome after their stroke. Post-stroke statin use was associated with a lower overall risk of the primary outcome (adjusted HR [aHR] = 0.66, p < 0.001). In sub-analyses, statin use was associated with a decreased risk of all individual outcomes, including osteoporosis (aHR = 0.68, p < 0.001), hip fracture (aHR = 0.59, p < 0.001), and vertebral fracture (aHR = 0.73, p = 0.003). A dose-effect relationship was identified. The aHRs for developing the primary outcome were 0.96, 0.86, and 0.34 for patients who used 1-90, 91-365, and > 365 cumulative defined daily doses of statins, respectively. These dose-effect relationships were maintained on subgroup analyses stratified by age, sex, and stroke type, and sensitivity analyses conducted without propensity score matching. Discussion: The main strength of our study is its nationwide populationbased design, large sample size, and sufficient follow-up period. However, the main limitation is that some clinical information was not available from the claims database, such as patient lifestyles as well as physical, psychiatric, or detailed laboratory examination data, all of which might be confounding factors. Conclusion: Statin use is associated with decreased risks of osteoporosis, hip fracture, and vertebral fracture in stroke patients. Further large-scale prospective studies or clinical trials are needed to confirm this finding. Background and Objectives: Spinal cord injury (SCI) is associated with low areal bone mineral density (BMD) and increased fracture risk; however, less is known about its relationship with volumetric BMD. This study assessed the feasibility of use of high resolution quantitative computed tomography (HR-QCT) in patients with SCI and sought to assess the relationship between SCI and volumetric BMD. Methods: Twelve patients with SCI were recruited to a study sited at the Osteoporosis Centre in Southampton. Information about the study was placed on social media, and through advertisements in the Spinal Injuries Association 'Forward' magazine. Participants underwent HR-QCT of the radius and tibia. At the same visit, patients also completed a self-reported questionnaire. Results were compared with estimated age and sexspecific means calculated from Dalzell et al Background: Normocalcaemic hyperparathyroidism (NHYPER) is characterised by persistently normal calcium levels, elevated PTH values on at least two consecutive measurements, after excluding other causes of secondary hyperparathyroidism. The prevalence of the disease in the literature varies significantly due to various definitions used; it is reported to be between 0.1 and 8.9%. The data on the natural history of this disease are sparse and inconclusive.
P32 ASSOCIATION BETWEEN CATARACT AND THE RISKS OF OSTEOPOROSIS AND FRACTURE: A NATIONWIDE COHORT STUDY
P33 ASSOCIATION BETWEEN STATIN USE AND THE RISKS OF OSTEOPOROSIS AND FRACTURE IN STROKE PATIENTS: A POPULATION-BASED COHORT STUDY
Objectives: to identify the prevalence of NHYPER in a UK referral population and study the variability of serum calcium. To compare the variability of serum calcium in NHYPER and primary hyperparathyroidism (PHPT). Methods: We retrospectively evaluated data from 6280 patients referred for a bone mineral density measurement. Using a statistical method (Mahalanobis distance) subjects were identified as 'normal' or 'abnormal' and using the reference intervals for albumin-adjusted calcium and PTH, these patients were divided in different categories. In order to identify NHYPER patients, we excluded the ones having either eGFR<60ml/ min/1.73m 2 or 25(OH)D<50nmol/l, or no measurements available. Repeated measurements of calcium were used to calculate the variability. Patients with PHPT were also identified; their variability was calculated and compared with the NHYPER group. Results: Based on laboratory results on the index day and the evaluation of their medical files, we identified 8 patients with NHYPER (prevalence 0.1%). These patients had laboratory results available for an average of 5 years and the natural history of this disorder was studied. Only 2 patients (0.03%) had consistent normocalcemia throughout their follow up. The SD for the NHYPER group was 0.101 mmol/L (CV 4.0%). Out of the 129 patients identified with PHPT, 27 fulfilled the above-named criteria. Only 48% had persistent hypercalcaemia. The SD of the PHPT patient group was 0.087 mmol/L (CV 3.2%). The comparison of the variances of the two groups showed no statistical difference (p>0.05). Discussion: The prevalence of NHYPER in our UK referral population is low. NHYPER patients often have episodes of hypercalcemia, so they probably suffer from PHPT. The variability of NHYPER and PHPT patients is similar, and this results in about half of patients with PHPT having normal serum calcium at some point.
P36 THE ASSOCIATION BETWEEN SEVERITY OF VERTEBRAL FRACTURE AND FUTURE FEAR OF FALLING AND CONFIDENCE
Usama Al-Sari, Jonathan Tobias, Emma Clark Bristol Medical School, University of Bristol, Bristol, UK Background: Vertebral fractures (VFs) are common and one of the most serious outcomes of osteoporosis. VFs can be graded as mild, moderate or severe based on a quantitative morphometric (QM) approach. No prospective studies have investigated the association between severity of VF and future fear of falling and confidence. Methods: This study is a prospective analysis of 700 women from a mixed community and secondary care-based cohort with a mean of 5.4 years of follow up. Lateral spinal imaging was taken at baseline, and VF were defined by QM either as moderate/severe VF (≥25% decrease in height) or mild VF (20%-<25% decrease in height). Fear of falling was assessed at 5 years follow-up by the Tinetti falls efficacy scale (FES), and general confidence using the Warwick-Edinburgh mental well-being scale (WEMWBS). Analyses were adjusted for age and additional self-reported confounders: alcohol, self-reported health, osteoporosis, use of stairs, walking speed, and falls as assessed at follow-up. Results: 395 women had follow-up data, 286 without, 58 with mild, and 69 with moderate/severe VF. Those with definite VF were older than women without VF (mean age of 77.6 vs 72.2). Women with definite VF also had worse general health and were more frail. There was a clear association between definite VF and future fear of falling on reaching into cabinets or closets (OR 3.04, 95%CI 1.25 to 6.10, P= 0.002), and getting dressed and undressed (OR 3.23, 95%CI 1.34 to 7.77, P= 0.048). There was also an inverse association between definite VF and general confidence (OR 2.25, 95%CI 1.06 to 4.76, P= 0.033). Associations between VF and fear of falling and general confidence were unchanged after adjustment for confounders. No association was seen between mild VF and either fear of falling or general confidence. Conclusion: Women with moderate/severe VF are less confident than those without fracture, and have greater fear of falling even after 5 years, which may contribute to their lower PA levels. No association was seen between mild VF and future fear of falling or confidence. Background: We previously demonstrated associations between maternal 25(OH)-vitamin D status, perinatal DNA methylation at the retinoid-X-receptor-alpha (RXRA) locus and offspring bone mass in a motheroffspring cohort, the Southampton Women's Survey. RXRA, a type II nuclear receptor, is known to heterodimerise with the vitamin D receptor, and has a key role in the nuclear action of 1,25(OH) 2 -vitamin D. Objective: We used an existing randomised trial, the Maternal Vitamin D Osteoporosis Study (MAVIDOS), to test the hypothesis that maternal gestational vitamin D supplementation would lead to altered perinatal DNA methylation at the RXRA locus. Methods: MAVIDOS is a multicentre, double-blind, randomised, placebo-controlled trial of 1000IU/day cholecalciferol or matched placebo from 14 weeks' gestation until delivery. Umbilical cord (fetal) tissue was collected at birth and frozen at -80 o C (n=453). Pyrosequencing was used to measure DNA methylation at 10 CpG sites within the previously identified RXRA locus. T-tests were used to assess differences between treatment groups in methylation at the CpG sites. Results: RXRA methylation levels were significantly lower in the umbilical cord from offspring of cholecalciferol-supplemented mothers, reaching statistical significance at 3 out of 10 CpG sites, for example at CpG 5: mean difference in % methylation between the supplemented and placebo groups was -1.98% (95% CI -3.65 to -0.32, p=0.02). Discussion: Encyclopaedia of DNA elements (ENCODE) evidence supports functionality of this locus with strong DNase hypersensitivity and enhancer chromatin within biologically relevant cell types including osteoblasts. Enrichment of the enhancer-related H3K4me1 histone mark is also seen in this region, as are binding sites for a range of transcription factors with roles in cell proliferation, response to stress and growth factors.
Conclusion:
We demonstrated, to our knowledge for the first time in a randomised controlled trial setting, that supplementation with cholecalciferol in pregnancy is associated with altered methylation at specific regions near to the RXRA promoter in fetal DNA. Our findings are consistent with previous observational results, and inform our understanding of early life mechanisms related to maternal vitamin D status, epigenetic marks and bone development.
Background: Treatment with glucocorticoids is the leading cause of drug-induced osteoporosis. However, osteoporosis risk assessment and management are often inadequate in long-term users of oral glucocorticoids. National Osteoporosis Guideline Group (NOGG) 2017 guidelines advise a case-finding strategy for patients at risk. Objective: The aim of the audit was to evaluate the implementation of NOGG 2017 guidelines for patients receiving long-term glucocorticoid therapy in a suburban general practice, instigate changes to ensure 90% of patients are investigated and treated appropriately, and to evaluate impact at a 6-month re-audit. Methods: The audit was performed in a general practice surgery of 5496 patients. Reporting Analysis and Intelligence Delivering Results (RAIDR) is a healthcare intelligence tool accessing GP clinical data. RAIDR used data on relevant osteoporotic risk factors to produce FRAX scores for patients who had been prescribed glucocorticoids 3 or more times in the past 12 months. FRAX data was displayed in a NOGG guidance graph for major osteoporotic fracture probability. Patients were assessed as high, intermediate or low risk. High and intermediate risk patients above the NOGG threshold were recommended to start bisphosphonates; these patients were sent a letter of explanation and a prescription for alendronic acid. There were no intermediate patients below the NOGG threshold. Low risk patients were recommended to have lifestyle advice; a leaflet was produced and sent to these patients. Results: Initial results showed only 25% of patients recommended to be on bisphosphonates were taking them. Steps were taken to educate the GPs in the FRAX tool and NOGG guidelines; the COPD annual template was amended to aid adherence by alerting the nurse to the number of glucocorticoid courses prescribed, with additional boxes for prescribing alendronic acid and printing the lifestyle leaflet; and 2-monthly RAIDR searches by the practice pharmacist were started. A re-audit 6 months later showed improvement to 92. Discussion: The audit demonstrated that a positive behaviour change can be achieved through collaboration between different members of the multidisciplinary team. Conclusion: This audit showed that education, reminders and simple computer prompts can greatly improve the implementation of NOGG guidelines for glucocorticoid-induced osteoporosis. Local unpublished data from an English ambulance service found that following ambulance call outs, 24-32% of the patients were not conveyed to hospital and of those, only 32-52% were referred to the local Falls Prevention Service for a specialist multifactorial assessment (NICE 2013) . Background: The literature review undertaken supported the need for a falls pathway (guidance for practitioners) to be in place. However it did not uncover the reasons for low referral rates of non-conveyed patients to falls prevention services. This presentation will outline the design of a study which aimed to: a) gain an in-depth understanding of the falls patient journey from patient, carer, and ambulance crew perspectives, b) generate a clear understanding of the ambulance service customs and practices which could inform improvement of the existing falls pathway. Methods: An ethnographic approach enabled paticipants' values, behaviours and beliefs to be explored. The methods were participatory observation and semi-structured interviews of patients / carers and ambulance crew. The sample was people over 50 years of age who had fallen or their carers (n= 10) who had been seen by the ambulance service. Ambulance crew were also recruited (n= 10). Results: The study gained an in-depth understanding of the experiences of crew and patients/ carers. For both ambulance crew and patients/carers, there were two shared themes 'falls journey' & 'falls not being a problem'. For crew 'training' was a theme, for patients/carers 'language' and 'patient transport'. In summary, the falls pathway in the local area was clearly understood and followed by all crew observed. The study shared the challenges of recruiting in a hard to reach group. Keywords: Falls Prevention, Ambulance service
P40 EXPERIENCES OF FALLS IN DOMESTIC SETTINGS AND USE OF AMBULANCE SERVICES: AN ETHNOGRAPHIC STUDY
P41 AN EXEMPLAR COMMUNITY FOUNDATION NHS TRUST INTEGRATED FALLS MANAGEMENT & FRACTURE LIAISON SERVICE Christina Heaton Falls Prevention & Fracture Liaison Service, Bridgewater Community Foundation NHS Trust, Wigan, UK
Introduction: The Nurse Consultant lead service is an integrated multidisciplinary service that provides specialist assessment, diagnosis and treatment for patients who suffer with falls, reduced balance and fractures. It provides lifestyle advice, investigations into bone density and underlying conditions and promotes bone health and effective treatment for Osteoporosis. We provide therapeutic interventions to improve strength, balance, mobility and function, which aim to improve confidence, and reduce risk of falls and fractures and promotes independence. Methodology: We assess patients who have had a fall or are at risk of falling over 18 years old and assess patient over 50 years old following a fracture. Through integrated working we provide effective and timely assessment and interventions for our patients. We work in partnership with the local acute NHS trust and other agencies such as local leisure trust, ambulance and fire services, local council, charities and national organisation such as the National Osteoporosis Society and their local patient forum. The established patient pathway ensures that patients who require secondary care are referred appropriately and in a timely manner, therefore providing a cost effective service. & Dexa outcomes -47% of patients assessed required a dexa scan, of theses; 45% had reduced bone density needing a follow up scan in 2-3 years; 30% required lifestyle advice only and 22% were diagnosed with Osteoporosis and medication was requested to their GP's. Clinical presentation: A 26-year-old man, presented to A&E with one week of feeling unwell with abdominal pain, lower limb vasculitic rash, arthritis involving the ankles and knees, metacarpophalangeal joint synovitis and bloody diarrhoea. His acute phase inflammatory markers were raised with an elevated IgA and low Vitamin D. A probable diagnosis of Henoch-Schonlein purpura was made and was treated with steroids to which he responded well. Investigation: An incidental finding of raised alkaline phosphatase (ALP) levels was observed after the initiation of steroid treatment. The ALP has remained persistently elevated between 300 and 500 IU/L (reference range 30 -130 IU/L). Renal profile and other liver function tests were normal. ALP isoenzyme electrophoresis showed marked increased intestinal fraction of ALP with marginally increased bone and normal liver fractions. There was no evidence of macro-ALP. Measurement of the bone turnover markers, serum bone specific ALP and total procollagen type-1 N-terminal peptide, showed a high bone turnover suggesting possible Paget's, fracture or other metabolic bone disease. However, the patient remained asymptomatic, with normal bone densitometry and whole body bone scans. Abdominal imaging showed some thickening of the terminal ilium with normal oesophago-gastroduodenoscopy and colonoscopy. Biopsy of the terminal ilium was unremarkable. Management: The patient initially was placed on Vitamin D supplementation and steroids for the vasculitis, but is now no longer on any medication. He remains asymptomatic and is currently being monitored annually as an outpatient by both rheumatology and metabolic bone teams. Discussion: Can vasculitis in the gut cause an increase in ALP? Or is it a benign biochemical finding? In our patient, no obvious or significant pathology has been directly linked to his marked elevated intestinal ALP (which can be associated with chronic renal failure, liver cirrhosis, IBD & diabetes mellitus). The underlying cause remains elusive. Here we illustrate and discuss the importance of measurements of ALP, both total and specific isoenzymes, to aid in diagnosis of liver, bone and intestinal diseases, their importance in determining the source of an increased ALP and the pitfalls of investigation. Objective: This study set out to evaluate firstly whether the NOS's programme of peer review is delivered in a way that is acceptable to both the peer review sites and peer reviewers and secondly whether the process has led to improvements in the delivery osteoporosis services.
P44 EVALUATING THE IMPACT OF PEER REVIEW FOR OSTEOPOROSIS SERVICES
Methods: An electronic survey about the benefits and impacts of the peer review was sent to all sites and peer reviewers. Responses to questionnaires which had been sent to peer review sites and members of peer review teams after a visit were also analysed. Results: All sites were satisfied with the peer review process and agreed with the conclusions of their peer review report. The majority of sites felt that most recommendations from peer review were realistic. However, most sites reported barriers to taking the recommendations forward, including a lack of funding, recruitment difficulties and a lack of engagement from senior management. The majority of sites reported that the peer review had led to improvements, particularly standardisation of processes, improved patient support, increased support from senior managers, improved networking opportunities and improved relationships with the NOS. For sites with an existing Fracture Liaison Service, the majority felt that the peer review helped improve this service. Peer review was viewed by peer reviewers as a good opportunity to learn from sites and to share their experience and good practice. The majority reported that the learning influenced their own clinical practice and/or service development and they felt valued and supported. Recommendations for change include providing advance information to peer reviewers in a more structured and succinct form. Conclusion: The NOS's peer review process is an acceptable and effective tool for service improvement. It is also a good opportunity for learning and sharing of experience for members of peer review teams. The evaluation identified some minor recommendations for change to the process and the peer review report. Background: A key role of the FLS is screening for secondary causes of osteoporosis. Myeloma is a recognised secondary cause and early diagnosis improves survival. The 2017 NOS Quality Standards listed myeloma screening as a special procedure depending on the patient's co-morbidities without explicitly defining the co-morbidities. In 2017, the local departments of Haematology, Immunology and Rheumatology agreed on a pathway for universal screening for myeloma based on serum electrophoresis, serum free light chains and urine electrophoresis. Objective: This audit examines the impact of this pathway within an FLS. Methods: We sampled 100 patients seen by the FLS between January and March 2018 needing bone therapy. The completion and outcomes of screening were checked using the hospital laboratory and FLS databases. Results: Of 100 patients sampled, 68 were female, 86 aged over 75 years and 41 sustained a hip fracture. Overall, 84 had serum electrophoresis measured, 81 had serum free light chain and 57 had urine electrophoresis. 52 patients had complete appropriate screening. The outcomes are shown in the table. For example, 3 patients had probable myeloma, of these 3/3 were women, 2 were aged over 75 years and 1 had a hip fracture. 3 patients were discussed or referred to haematology, 21 required additional primary care testing, 3 were already known MGUS and 4 patients subsequently died. Conclusion: Addition of universal myeloma screening to laboratory testing of 100 patients, identified 3 patients with myeloma who would have been missed. Discussion: Further analysis of a larger sample of patients is needed to clearly define the patient co-morbidities that require myeloma screening within an FLS setting, establish the benefits vs. costs and methods to improve screening completion rates. Outcome of myeloma screening in 100 FLS patients requiring bone therapy: Background: Loneliness is a state of subjective experience that occurs when the number of friendships or relationships someone has is smaller than desired (social loneliness) or when someone is missing intimacy from their relationships, friendships or acquaintances (emotional loneliness). In the UK 5-16% of people aged ≥65 years experience loneliness most or all of the time and a further 30% sometimes. Osteoporosis and resulting fractures cause much morbidity including pain which may inhibit social interaction. Objective: The aim of this service improvement project was to assess the prevalence of both social and emotional loneliness in patients attending osteoporosis clinics. Methods: A cross-sectional survey across 2 osteoporosis clinics was performed. The De Jong Gierveld Loneliness Scale [DJGLS](measures Emotional and Social loneliness) were used to assess loneliness . The social loneliness questions enquire about whether there are people the subject can rely on, trust or feel close to. The emotional loneliness questions enquire if the subject has a sense of emptiness, rejection or missing people around them. SPSS version-17 was employed to analyse the data. Results: 108 osteoporotic patients, mean age 72.2 years (SD=9.3), (range=54-92), 95 female (88%) were assessed. 50.9% (n=55) reported some degree of emotional loneliness, compared to 27.8% (n=30) reporting social loneliness [Chi2=16.9,p<0.001]. For emotional loneliness, 25% (n=27) experience a general sense of emptiness, 11.1% (n=12) feel rejected, and 40.7% (n=44) miss having people around them. For social loneliness 22.2% (n=24) cannot trust many people completely, 9.3% (n=10) do not have enough people that they feel close to, and 14.8% (n=16) do not have plenty of people they can rely on when they have problems.
P45 THE IMPACT OF MULTIPLE MYELOMA SCREENING WITHIN A FRACTURE LIAISON SERVICE (FLS)
Discussion: Symptoms of loneliness are not uncommon in osteoporotic patients. Some degree of emotional loneliness was present in a half and some degree of social loneliness occurred in just over a quarter of osteoporotic patients. Further research is needed into factors leading to loneliness in this group. Conclusion: Clinicians should be aware of this loneliness issue in osteoporosis, particularly emotional loneliness which was twice as common as social loneliness.
P47 DIFFERENCES IN BONE DENSITY AND DEMOGRAPHICS BETWEEN TAMOXIFEN AND AROMATASE INHIBITORS (AI) COHORTS
Bradley Lonergan, Marwan Bukhari Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, UK Background: Breast cancer is the most common cancer in the UK with 54,900 new cases every year. Aromatase Inhibitors (AIs) are generally associated with less side-effects than tamoxifen (including less weight gain). However, average bone loss of 1-3% per year on AIs, and greater loss in younger women, leads to increased fracture rates compared to tamoxifen. Bone assessment and bisphosphonates or pre-treated with tamoxifen can reduce bone loss. Objectives: This study aims to determine any differences in Bone Mineral Density (BMD)/T-score/Z-score at different bone sites, age, weight and risk factors for breast cancer patients prior to treatment with tamoxifen or AIs. Methods: 398 female breast cancer patients were treated with tamoxifen (51 females) or AIs (347 females) at Morecambe Bay Hospital Trust (MBHT) from 2006 to 2013. Data was extracted from a trust DEXA database and oncology patient data. Stata 13.0 software was used to perform univariate t-testing, multivariate logistic regression and chi 2 analysis for tamoxifen and AI cohorts. Results: Univariate t-test analysis showed that weight, bone mineral density right neck of femur, T score right neck of femur and Z score right neck of femur were significantly different between the groups. On multivariate logistic regression, age (p 0.005, CI 0.057-0.322), weight (p 0.000, CI -0.224-0.076) and T score L4 (p 0.018, CI -0.933-0.0886) were significantly different. Using chi 2 testing, Rheumatoid Arthritis (RA) (p 0.009) was found to be more common in the tamoxifen cohort. Discussions: AIs are unsurprisingly more popular in post-menopausal women given the comparatively greater bone deterioration in premenopausal women. They are less popular with rheumatoid patients, possibly due to co-morbid bone risks, and may prevent further weight gain in heavier patients. Initiating AIs in women with good baseline bone density may help to reduce complications of treatment. Conclusions: A cohort starting AIs were found to be significantly older, of greater weight, more likely to have RA and superior Tscores at L4 when compared to those treated with tamoxifen. Stratifying older women with greater bone density and greater weight may minimise adverse outcomes.
P48 ONE STOP CLINIC AS A STANDARD OF OUT-PATIENT CARE FOR DENOSUMAB ADMINISTRATION
Anish Gandecha, Dee Tomasso, Thushani Wickramaratne Rheumatology, Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK Background: Denosumab is a treatment option for the primary and secondary prevention of osteoporotic fragility fractures. However the use of Denosumab in our hospital was significantly low and a higher number of patients received Strontium ranelate. Since the withdrawal of Strontium ranelate in August 2017, the need for an alternative treatment that can be delivered by a safe, effective and efficient service was salient. With this in mind we developed the one stop clinic in our FLS service. The service is in operation since Sept 2017. Objective: To evaluate the performance of a 'one-stop' clinic by a patients satisfaction tool to measure the quality of our new service. Methods: Patients eligible for Denosumab were pre-selected by the lead consultant for FLS service. Data was collected retrospectively from December 2017 to May 2018. Patients who had received their first injection within the last 6 months were identified from a nurse led osteoporosis clinic list. A patient questionnaire was designed with answers recorded and analysed by a telephone conversation. Results: 18 patient questionnaires were completed. Total number of patients was 44. We were able to speak directly to only 18(40.9%). All patients (100%) recalled a discussion about their disease and the treatment options. 16 (89%) were able to recall how many injections they required over the correct time line, the remaining 2 provided an answer with an incorrect injection schedule. All but 1 patient (94%) took a blood test to check for serum calcium level 2 weeks after.4 patients (22%) reported side effects following the injection. Rash in 11% myalgia in 5.5% a dry, sore mouth in 5.5%.were noted. 89% were very likely (10 out of 10) to recommend the Denosumab injection service. Two patients said it was too early to comment. One patient (5.5%) suggested improving service by providing literature on Denosumab. Discussion: The results are promising that patient centred individualised care can be delivered in a one -stop clinic. Successful education increases patient satisfaction and results in improved adherence to treatment and a better clinical outcome. Conclusion: We will need to continue to gather more data as it demonstrates that patient satisfaction is an important indicator tool in measuring the quality to achieve a safe, efficient and cost effective health care in the current challenging times. Background: The National Hip Fracture Database collects measures of morbidity and mortality but does not highlight specific post-operative complications. We have been collecting this data locally and have noted a high prevalence of chest infections. As a result, a number of interventions were implemented, such as Bsit up if not out^day one, increased use of spinal anaesthesia, ward based junior doctors (from August 2016), lower threshold for respiratory physiotherapy and patient education. Objective: To evaluate the impact of previous interventions over a three year period from 2015 to 2017. Methods: Following the introduction of these interventions, data was collected prospectively from 958 patients over a three year period. We excluded thirteen patients from analysis as they were not managed operatively. All ages were included. Results: The data demonstrates a significant reduction in the incidence of chest infections among the hip fracture patient population from 27% in 2013-14 to just 16.5% in 2017. The percentage of patients sitting out on day one has not changed during this period, averaging 75%. Rates of spinal anaesthesia have increased from 9.5% in 2015 to 16.7% in 2017. The national hip fracture database demonstrates a reduction in 30-day mortality from 12% in early 2015 to 8% in 2017. Conclusions: There has been a significant reduction in the incidence of chest infections over the last three years, suggesting that our interventions have helped to improve the quality of patient care and patient outcomes.
P50 FRAILTY AND HIP FRACTURES
Rachel Bradley, Sonu Dennis Orthogeriatrics, University Hospital Bristol NHS Foundation Trust, Bristol, UK Background: Hip fractures are often seen as a marker of frailty. Frailer patients should ideally be prioritised in term of Orthogeriatric review and the Best Practice Tariff (BPT) targets as they have a greater morbidity, mortality and length of stay, but does this actually happen in clinical practice? Objectives: To study the frailty of hip fracture patients presenting to a Trauma Unit and their outcomes, in order to inform clinical practice. Methods: The Rockwood Clinical Frailty Score (FS1-9) was calculated on all hip fracture patients by the specialist nurse. A score of 4 is described as 'vulnerable', 5 'mildly', 6 'moderately', 7 'severely' and 8 'very severely' frail. Data on age, residence, time to theatre (BPT), Orthogeriatric review (BPT), acute length of stay (LOS), rehabilitation, discharge destination and death was also collected. Results: 397 patients were discharged between Feb 2017 and 1 st April 2018. Frailty scores were not recorded in 22 leaving a total of 375. In this study 5.8% patients were <60 years. Frailty scores increased with age. The majority of hip fracture patients admitted had a score in the midrange FS4-6 and were mobile with the use of aids. Frailer patients were more likely to be operated on <36hrs; 83.3% FS7 compared to 50% FS1. However, an Orthogeriatric review <72hrs occurred in 50-65% of patients but did not appear to discriminate between age or frailty. The average LOS increased from 3 days FS1 to 24 days FS7. 44% of FS3 patients returned to their own home, whereas 22% of FS6 patients were admitted to a new Nursing Home. Thirty day mortality increased with frailty; 14.7% FS6 and 25% FS8. Discussion: Time to theatre appeared to prioritise those who were frailer, but Orthogeriatric liaison did not. This was due to limited capacity and the prioritisation of new hip fractures in order to achieve the BPT targets. A service redesign needs to be considered in light of these findings. Those with a frailty score of 4 to 6 may have the most to gain from greater Orthogeriatric and multi-professional input in order to improve patient outcomes. Case 1 involved a female aged 38, coming for a first DXA scan.ne m Clinical details were HIV encephalopathy, low BMI with previous long term steroids. The question to 'find the patients Bone Mineral Density'? The patient was travelling from a care home, who needed a hoist to transfer and was accompanied by a carer as she was unable to communicate. We soon found that the patient has the incidental finding of a left fractured hip, which has not been documented, is unknown to the carer and can't be communicated by the patient. The DXA scan can be continued with the right hip and spine being scanned. The question is, 'what to do next with this incidental finding'? Case 2 involves a paediatric male patient, which highlights reduced bone density with delayed bone age. His clinical details are Duchenne Muscular Dystrophy, and was due to start regular prednisolone therapy. Again the question was to find his Bone Mineral Density. The patient had a previous x-ray to his Left Hand and wrist, which is used to compare against the bones in a standard atlas, and using 'Greulich and Pyle', gives an estimated bone age, which was reduced in this case. This was the patient's first visit, and will be coming back regular for monitoring of his BMD (Spine + Whole Body minus Head) following treatment.
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ADULT HYPOPHOSPHATASIA: A DISEASE WHERE THE CLINICAL COMPLICATIONS COULD BE AVOIDED BY CAREFUL EVALUATION OF PATIENTS Marian Schini, Richard Eastell Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK Background: Hypophosphatasia (HPP) is a rare disease that has to be excluded before starting treatment for osteoporosis; HPP patients are more prone to develop atypical femur fractures (AFF) from bisphosphonates. Clinical presentation: A 47-year old woman was referred for bone mineral density (BMD) because of a family history of osteoporosis. Investigations were performed because BMD was below the average for age and the results were reported as normal. A year later, she was prescribed on alendronate. At the age of 54, she sustained two metatarsal fractures. The following year she started noticing odd sensations at her hips and at the age of 56, she tripped and sustained a complete left and an incomplete right femur fracture (considered to be AFFs due to bisphosphonate use). The patient was then referred for further evaluation. Her past medical history included loss of upper teeth at the age of 20. Her family history included metatarsal fractures in her mother. Investigations: Investigations were performed three months after the fractures and showed the following: ALP 42 IU/L (30-130), P1NP 86 μg/L (30-78), bone ALP 12 IU/L (9-28). Due to the medical history and the low-normal bone ALP, PLP was measured and was 190 nmol/L (40-100). Management: The diagnosis of HPP was established and the patient will be sent for genetic testing. The femur fractures were treated surgically with intramedullary nails and 2 months later there was evidence of callus formation. Conclusion: This patient's ALP was normal on two occasions and the diagnosis of HPP was established after she sustained the fractures. Previous measurements of ALP performed on this patient were low but were ignored. The learning point from this study is that patients considered for treatment with bisphosphonates should be evaluated thoroughly and previously performed investigations should be taken into account. & 9/17 would undertake genetic testing for familial osteoporosis (case dependant). Discussion: Genetic testing practice for FOP varies widely across the UK and Ireland. Most centres do receive referrals for FOP but rarely. Genes and gene-panels considered for testing through our survey include; ALPL, LRP5 (OP-pseudoganglioma syndrome), WNT1 (early onset OP), PLS3 (if X-linked), low bone mineral density panel (in house whole exome sequencing, Guy's) and the Sheffield osteogenesis imperfecta gene panel (which includes WNT1, BMP1, OI genes and several others). Testing is based on individual family histories and phenotypes. Conclusion: As genetic testing mainstreams, testing for genes in multifactorial disorders like FOP will increase. Collaboration and sharing practice between geneticists and expert colleagues (e.g. those looking after patients with FOP) is more important than ever. Our survey shows that although rare, referrals for FOP are received by clinical genetics and testing is considered. Background: Delirium is the most common complication of hip fracture. Polypharmacy is common in patients with this injury and hospital admission presents an opportunity for medication rationalisation as part of comprehensive falls risk assessment. The cumulative burden of anticholinergic medication has been associated with increased risk of delirium and persistent cognitive decline. We set out to define anticholinergic burden in this patient population and to examine how this changes during their admission. Methods: We reviewed admission and discharge medication for patients presenting with hip fracture between JanuaryMarch 2018. Anticholinergic Effect on Cognition (AEC) score was calculated for each patient. Results: 110 patients were admitted with hip fracture in this period. We excluded patients who had been repatriated to their local hospital before discharge (n=4), were still inpatients at the point of data collection (n=10) or who were deceased (n=18). Of the remaining 78 patients, 13 (16%) had a prior diagnosis of dementia. Despite comprehensive, repeated medication reviews by orthogeriatricians throughout the patients' stay, 62 patients (79%) had a net gain in the total number of medications prescribed. This increase in polypharmacy predominantly reflected new prescriptions for bone protection (30%) and the temporary need for analgesia (20%), aperients (17%) and thromboprophylaxis (12%). 46 patients (59%) had at least one admission drug discontinued. 20% of discontinued medications had hypotensive effects. 18 patients (23%) had an AEC score >1 on admission, rising to 22 patients (28%) on discharge. Antidepressants and antipsychotics accounted for the majority of anticholinergic medications prescribed.
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Mirtazapine was the single most common significantly anticholinergic medication on these patients' admission drug charts (14% of prescriptions with AEC score), as well as the most common anticholinergic commenced in hospital. Discussion: Close collaboration with ward pharmacists is key to the care of patients with hip fracture. This failure to reduce anticholinergic burden despite our proactive approach is disappointing, but many culprit drugs were antidepressants so their discontinuation during the acute admission might have affected patients' morale and rehabilitation. Background: National and local data show that an increasing proportion of patients attending the Emergency Department with falls, collapses and injuries are elderly. These patients are more likely to suffer from significant trauma with minimal mechanisms, (such as fall from standing height). Historically, such 'silver trauma' is under assessed, underdiagnosed and undermanaged. Objective: To adequately assess a minimum of 75% of 75+ year olds attending the Emergency department for silver trauma. Thus ensuring early identification of all potential injuries and referral to the appropriate specialties. Methods: This was a quality improvement project of 3 PDSA (plan, do study, act) cycles. Through baseline data collection, multi-professional key stakeholder consultation, and a review of current triage triggers, it was found that there was no effective tool to meet our objective. We therefore developed a new silver trauma checklist, based upon a minimum standard agreed by departmental leads, (Emergency, and orthogeriatric representatives). This was introduced alongside a crossdivisional communications package in a stepwise manner, assessed using PDSA methodology. Results: Baseline data showed that 0% of patients had a documented assessment meeting the minimum standard. Following the introduction of the checklist (cycle 1), we found it was present in 29% of notes. Of these forms, 84% were filled out, (38% fully complete, 46% partially complete). For cycle 2, the checklist was present in 39% of the notes, will 65% of them filled out, (39% fully complete, and 26% partially complete). The latest PDSA cycle (3) results showed the checklist was present in 63% of notes. Of these forms, 79% were filled out, (36% fully complete, 43% partially complete). Secondary findings whilst collecting the data were a reduction in the number of missed fractures, and an improvement in overall trauma documentation quality. Discussion: We have demonstrated a gradual and continual improvement in both the number of patients assessed appropriately and an increased awareness and enthusiasm of the hospital staff towards silver trauma. Conclusion: On-going work to further embed and sustain our objective is in progress, and we are close to achieving our objective. level ≥25nmol/L, while the European Food Safety Authority (EFSA) recommends at least 50 nmol/L. These levels cannot be achieved without intervention. Objective: A non-randomised feasibility study of the effects of limited exposure to narrow band UVB therapy to the face and forearm on serum 25OHD levels in healthy volunteers. Methods: Participants with Skin types II, III (Fitzpatrick photo typing scale) on no more than 400IU (10mg) vitamin D supplementation daily during the two preceding months were recruited between November, 2017 and April, 2018. Participants with skin malignancy or premalignant lesions, on immunosuppressive or photosensitivity inducing medications were excluded. A NB-UVB dose of 1 standard erythema dose (SED) on the first day and thereafter 2 SED on each of the following 6 days was given to face and hands using a portable cabinet with 3 Philips PL-36 watt 01 twin Narrowband tubes at 30 cm distance with safety goggles. Serum 25OHD was measured 2 weeks after exposure and, if 25OHD <50nmols/l, a second and, if necessary, a third course of treatment were offered. Summary statistics and paired sample t-tests are presented. Results: Of 15 participants with 25OHD3 <50nmol/L originally recruited, data are available on 7 participants who completed the study. Baseline [range] 25OHD was 29.8[15.6-42 .0] nmol/L. There was a significant increase (all at least p<0.05) in 25OHD compared with baseline: to 33.6[24.3-46 .5] nmol after the first, 33.9[26.5-41.4] second and 34.7[25.2-44.7 ]nmol/L third courses of NB-UVB. Discussion: NB-UVB therapy is a feasible treatment for vitamin D deficiency and insufficiency. We saw greater than anticipated attrition but have ethics approval to extend the study into 2018 winter months to complete recruitment. There was a significant rise in 25OHD, with all participants achieving a level of at least 25nmol/L, although none achieved a 25OHD level of 50nmol/L. Conclusion: Narrow band UVB increases average Vitamin D levels in participants with Fitzpatrick skin type II or III, achieving the SACN recommended levels of circulating 25OHD of at least 25nmol/L. We need to study this in larger cohort to assess response. Background: Over last few years, teams have been developed in the community to reduce secondary care referrals and to develop services in primary care. Our service has morphed from a nonfunded multidisciplinary meeting to a fully organised virtual clinic assessing patients in their usual place of residence and delivering specialist care closer to home. Objectives: To setup a fully functional bone health service in primary care delivering specialist osteoporosis assessment and treatment including intravenous Zolendronic acid infusions. Methods: A team of 4 specialist bone health nurses were trained to start assessing patients who had osteoporosis and those at risk of fractures. Close links were established with secondary care physicians and regional osteoporosis services. One of the consultant geriatrician started working with the team to develop this service. Nurses started assessing patients in primary care clinics, at home and in care homes. Routine investigations such as bloods and DEXA scan are also requested and interpreted. The cases are then discussed with the geriatrician and plans formalised. Results: In the last 6 months, the team has reviewed 106 patients in the virtual clinic. Only 8 patients were referred to secondary care, 3 of those for Denosumab as it is not available in the community. 4 patients declined any assessment or intervention and 2 patients have not had their interventions completed. (see table 1).
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Discussion: On average 15 patients were discussed in each clinic and over time, the team has become much more confident and autonomous in the management of complex patients. Conclusion: This review is able to show that specialist care can be safely and cost effectively delivered in primary care. Virtual clinics as a service is the way forward and needs now to be evaluated in a trail. Background: Physiotherapy is a core component of rehabilitation following a hip fracture. Approximately 40% of people sustaining a hip fracture will have dementia but there is little evidence to guide physiotherapy interventions in this population. Objective: The aim of this study was to determine the feasibility and acceptability of delivering a physiotherapy intervention designed following hip fracture for community-residing people with dementia.
Methods:
We undertook a multi-site, single-arm, mixed-methods feasibility study. We aimed to recruit twelve participants with hip fracture and dementia from four step-down or community-rehabilitation services in the South West of England. Community-based physiotherapists and assistants were trained in delivering the intervention, which comprised functional exercises and behaviour change strategies. Quantitative data collection explored recruitment while the qualitative data sought to explain recruitment, the feasibility and acceptability of delivering the intervention, and its acceptability to patients. Results: We screened 800 people but were able to recruit only one person into the study, and they subsequently withdrawn due to hospital readmission. Focus groups with physiotherapists suggested that the intervention would be feasible to deliver and highly acceptable to clinicians but our inability to recruit meant we could not explore acceptability to patients. Discussion: It was not feasible to recruit people to the study as they were not referred for physiotherapy following discharge from the acute setting.
Reasons for this were reported to be resource pressures and lack of knowledge about treating people with dementia alongside a pressure to focus on physical impairments rather than a person-centred approach. Physiotherapists described historically using this impairment-based approach to rehabilitate this population. Conclusion: Our findings suggest that physiotherapists struggle to determine the potential rehabilitation of people with dementia following hip fracture. We found signs of therapeutic nihilism, whereby it is assumed that people with dementia cannot be rehabilitated, so they are not given the opportunity. Future recruitment pathways need further exploration and may involve identifying potential participants in the acute setting.
P59 THE IMPACT OF A LOW-COST DIGITAL AND PRINT AWARENESS CAMPAIGN ON PATIENT BEHAVIOUR IN RELATION TO PERSONAL RISK OF OSTEOPOROSIS AND FRAGILITY FRACTURE
Claire Bovey National Osteoporosis Society, Bath, UK Background: The National Osteoporosis Society (NOS) 'Stop at One' campaign targets people aged over 50 who have broken a bone. It encourages people to find out through an online quiz on the NOS website: 1) if they are at risk of osteoporosis and 2) how to take action to reduce their fracture risk. A low-cost marketing intervention was trialled making printed campaign materials available direct to patients at the point of care (fracture clinics). Introduction: RCP as well as NOS guidelines include radiological osteopenia as an indication for referral for DXA scan. We looked at if radiological osteopenia on a plain x-ray is a useful indicator to further assessments on its own. Materials and Methods: Our service has been keeping a database of the bone density scanning activity. The clinician reporting on DXA scan also completes a database sheet. We analysed the database activity for a period of 48 months from September 2009-August 2013. Discussion: During the 48 months period, a total of 8080 patients were scanned. 5620 (69%) were referred by GPs and remaining 2460 by hospital clinicians. 6804 (84%) were female and 1276 (16%) were male patients.695 (8.6%) patients were referred with 'radiological osteopenia reported by reporting radiologist' as one of the indications. 584 (84%) of these were female and 111 were male patients. 573 (82.5%) of 695 were above age 50 years. In 169 of these 695 patients the referral had identified additional cause for referral for DXA including fracture, steroid use or secondary osteoporosis. Of 695 patients, 228 (32.8%) had normal BMD, 322 (46.4%) had osteopenia and 145 (20.8%) had osteoporosis. In normal BMD group of 228 patients, only 7 (3%) had previous fragility fracture, 4 (1.7%) had rheumatoid arthritis and 39 (17%) were smokers. While in osteoporosis group of 145 patients, 14 (9.7%) had previous fracture, 3 (2%) had rheumatoid arthritis and 78 (53%) were smokers. Conclusion: This preliminary analysis suggests that radiological osteopenia on a plain x-ray on its own is less likely to be useful indicator for underlying osteoporotic process, unless there are accompanying other clinical risk factors. This analysis is likely to have confounding factors. Further prospectively planned study would be advisable.
P61 AUDIT OF DEXA SCANS FOR WOMEN OVER THE AGE OF 75 WITH PREVIOUS INSUFFICIENCY FRACTURES Leila Solomons
Radiology, Nuffield Health Hospital, Bournemouth, UK Background: Women with a prior fragility fracture should be considered for treatment without the need for further assessment, although bone mineral density (BMD) measurement is sometimes appropriate particularly in younger postmenopausal women. (NOGG 2017 guidelines). Objective: In this audit, the researcher examined how many women over the age of 75 with previous insufficiency fractures were given DEXA scans in our department. The NOGG 2017 Guidelines state that scanning these women is unnecessary, however five women over the age of 75 with previous insufficiency fractures were scanned over the last year. Method: The researcher used four screening variables on every female patient scanned between 1st Oct 2017 to 30th Sep 2017 to determine whether patients should be included in this study: age, speciality of referrer, reason for referral and T-score of the left femur. Results: 10 women out of the 97 scanned in the time period fitted the target group. Of these, 5 had previous insufficiency fractures, 5 had not. When the scan results were assessed using the FRAX tool, of the 5 with previous fractures, 2 were above intervention thresholds, 2 were below and 1 was unable to be assessed. of the 5 patients without previous fractures, 3 were above the intervention thresholds, 1 was below and 1 was unable to be assessed. Conclusion: The 5 patients scanned who had previous fractures made up 5.15% of our total workload and were scanned against the NOGG 2017 guidelines. The researcher was unable to find evidence available to indicate whether this result is significant, the results were discussed with the clinical lead for bone densitometry and the following actions were put in place. The guidelines are to be discussed with the relevant consultants to ensure appropriate referrals to the service. Our justification process has been reviewed and ratified and the audit is to be reviewed in 12 months' time. Introduction: Rheumatoid arthritis (RA) is associated with inflammation that induces many changes in skeletal health. This study used high resolution quantitative peripheral computed tomography (HRpQCT), to assess volumetric BMD/bone strength in patients with RA. Methods: Fifty nine (41 female, 18 male) patients with RA were recruited to a study sited at the Osteoporosis Centre in Southampton. Subjects underwent HRpQCT of the radius and tibia to assess various indices of bone health, including cortical and trabecular BMD, trabecular thickness, trabecular separation and cortical porosity. Scans with excessive motion artefact were excluded. Fifty five (39 female, 16 male) patients had either radial or tibial scans available. At the same visit, patients also completed a selfreported questionnaire on age, gender, height/weight, time since RA diagnosis, co-morbidities, medications use TNF-i and steroid use and smoking/alcohol-consumption. We recorded RF/CCP status, physician assessment of disease activity, and patient assessment of disease activity from patient records. Results were compared with estimated age and sex-specific means calculated from Dalzell et al (1). Results: Fifty-five patients with RA were included in this study. The mean age was 55.8 (SD 12.6) years. The median disease duration was 11.4 years . Mean BMI was 27.2 (SD 5.8). Forty nine (90.7%) subjects were RF or CCP positive, with disease severity ranked as severe in 33 (61.1%) and moderate in 20 (37.0%). Fifteen subjects (27.8%) had ever taken steroids and 47 subjects (85.5%) were receiving TNF-i medications. Radial trabecular number and density were lower, and trabecular separation greater than expected in our study sample (p<0.05); tibial results were similar (p<0.10 for trabecular number and separation). We did not observe alteration in cortical values that reached statistical significance in this sample. Disease duration and severity were not significantly associated with micro-architectural alteration, though ever use of steroids was associated with radial periosteal circumference (p<0.05, adjusted for sex) and use of TNF-i agents with radial total and trabecular area (p<0.05, adjusted for sex). Background: Vertebral fractures are the most common osteoporotic fracture in patients over the age of 60 and are associated with reduced quality of life, chronic pain and premature death. They are often undiagnosed and may occur in patients who have normal/ osteopaenic BMD readings. As FRAX is calculated using femoral neck BMD scores, some patients with spinal osteoporosis and undiagnosed vertebral fractures may not meet the threshold for fracture prevention treatment. Objective: To evaluate whether using vertebral fracture assessment (VFA) in patients with spinal osteoporosis who do not meet the treatment threshold, changes treatment recommendations and/or treatment given. Methods: A protocol was developed to perform a VFA in patients referred for first DXA with T-score <-2.5 at the spine, T-score >-2.5 at the femoral neck and a FRAX score <10%. VFAs are reported by Bone Density Technician and Consultant Rheumatologist indicating presence, absence or suspicion of vertebral fracture. All patients who had a VFA between March 2017 and February 2018 were followed up using the electronic health record and medical GP prescribing records to identify if fracture prevention treatment had been commenced. The most common site of cervical spine fracture in the elderly is the odontoid process. These fractures result predominantly from ground level falls. Osteoporosis has been identified as an important predisposing risk factor. Objective: This study aimed to evaluate the management of older patients with cervical spine fractures and identify opportunities to reduce fracture rates. Methods: A service evaluation was undertaken utilising a retrospective review of electronic hospital records at the Royal Devon and Exeter hospital for patients aged 50 years and over who sustained a c-spine fracture over a 4 year period. Patients were identified from CT c-spine reports positive for fracture. Results: 85 patients (mean age: 77.25y, SD±12.70) were identified. 61.2% sustained c-spine fractures from a ground level fall. Prior to fracture 11.8% had a DXA scan, 12.9% diagnosed osteoporosis and 9.4% has bisphosphonate use recorded. 41.2% had sustained at least one previous fracture of any bone and 20% prior vertebral fractures. Radiographic osteopenia was mentioned in imaging reports, prior to or on the day of c-spine fracture, in 17.6%. Mortality at 3 and 12 months were 11.8% and 20.8% respectively. One year following c-spine fracture, a further 5 people had a DXA and 1 more person was taking a bisphosphonate. Five people attended the hospital with a fracture within a year of the c-spine fracture, four of which were NOF fractures. Discussion: Mortality rates are similar to those published in other studies. Opportunities for intervention to reduce future fractures were missed after: previous low trauma fractures, reports of radiographic osteopenia and low trauma cervical spine fractures. Fracture prevention is not an integrated part of c-spine fracture care despite their association with osteoporosis in the elderly. In the absence of an FLS, close working of clinical teams is needed to ensure action is taken to reduce fracture rates of cervical spine and other fractures. Background: NICE QS149 recommends assessment of 10-year fracture risk, using either QFracture or FRAX. Although equivalence is implied, important differences in algorithms, datasets, calibration and output (mortality-adjusted fracture probability versus expected incidence) may affect patient-level performance. Objective: To compare the performance of FRAX and QFracture in a real-world setting. Methods: 10-year risks of any major osteoporotic fracture (AFR) and hip fracture (HFR) were estimated for 70 unselected adult referrals (59 female), of mean (SD) age 69 (10.8) years, using FRAX without (FRAX-) and with (FRAX+) femoral neck (FN) T-score, and QFracture. All available risk factors used by both risk engines were employed, and quantitative outputs compared to published thresholds for assessment and treatment. Results: 83% of patients had at least one risk factor for osteoporosis, and 45% reported one or more fractures. 3 patients had insufficient data to complete a FRAX score. Mean (SD)T scores were -1.6 (1.2) and -0.98 (1.7) at the femoral neck and lumbar spine, respectively, with discordant results in 9 patients. FRAX estimates were significantly higher without BMD for AFR (mean [SD] Background: Osteoporosis is a prevalent bone disease characterised by low bone mineral density and increased fracture risk. As bone loss associated with osteoporosis is symptomless, silent and progressive, the need for an accurate fracture prediction model is crucial. The gold standard for identifying osteoporosis and increased fracture risk is through quantification of bone mineral density (BMD), using dual energy X-ray absorption. Unfortunately, BMD is not without limitations and only identifies~60% of potential fractures. Arguably, this is because BMD does not measure the multiple material factors that contribute to bone strength. Objective: Rather than depending exclusively on the 'mass' of bone, our research investigates predicting the risk of fracture using 'bone quality'. This additional information is obtained from the microarchitecture using micro computed tomography (μ-CT) and bone chemistry using X-ray diffraction (XRD). Alongside the fundamental science, this research also aims to develop a new technology, Focal Construct Geometry (FCG), which is hoped can measure XRD signatures in vivo. Methods: Human bone specimens were collected from the femoral head of over 100 osteoporotic and 'normal' donors. Each specimen was scanned using a Nikon CT H225 cone beam μ-CT scanner. XRD analysis was carried out using a PANalytical X'Pert PRO Multi-Purpose Diffractometer with Cu Kα radiation. Results and Discussion: The results obtained in the laboratory suggest there are microarchitectural and physiochemical differences between fractured and non-fractured tissue. The physicochemical differences were not only highlighted when comparing quantitative XRD data but also through principle component analysis (PCA), which was applied for the first time to raw diffraction signatures. The technology (FCG) has been developed during this research using animal bone and soft tissue analogues, with the results suggesting it may be possible to obtain the physicochemical properties of the bone in vivo with the same precision as those obtained within the laboratory. Conclusion: For the first time, this work highlights the clinical value of new biomarkers for fracture risk prediction. Thus, in order to improve fracture prediction models, diagnostic tools need to be developed which measure BMD as well as bone quality. Background: Guidelines are lacking on the screening and management of low bone mineral density (BMD) in patients with inflammatory arthritis (IA), who are at high risk of compromised BMD because of the disease, steroid usage and other risk factors. There is also individual variability regarding follow up imaging. Objectives: To audit the screening and management of low BMD in IA within a Rheumatology Rehabilitation Unit. Methodology: Patients admitted from 14 th Aug to 31 st Dec 2017 were enrolled in the audit after informed consent. Parameters analysed included screening for low BMD since diagnosis, appropriateness of medications, education on lifestyle and exercises, repeat DEXA interval and the type of scanner. Data was collected by review of medical record, face-to-face and telephonic interviews. It was analysed with SPSS. Results: A total of 50 (45 females, 5 males) patients were included. 11 patients had no DEXA planned since diagnosis and 1 was awaiting. 18 patients did not have FRAX screening. 8 patients had DEXA within 2 years of diagnosis. Out of those who had the DEXA, 5 never had a repeat scan and only in 15, it was repeated within 5 years. 20 had the DEXA scan on the same machine. 5 patients had osteoporosis on scan out of which 4 were on bone protection. 19 patients had osteopenia out of which 18 were on calcium and vit D supplementation. 34 out of 50 stated they did not receive education on bone health and DEXA scanning during admission. 18/50 did not receive life style advice and 3/50 were unfamiliar with weight bearing exercises. Discussion: Timely and regular assessment of fracture risk is essential in patients with IA . Our audit indicates that there is lack of clarity on best practice in the timing of assessment of bone density after diagnosis and subsequent follow up. It also showed that majority of those with low bone density were on the appropriate bone protection. Follow up DEXA was performed on the same machine for all the patients. There should be more focus on educating patients about the screening process and its significance. In this case review we present several interesting cases from our own practice demonstrating additional findings found on dual energy x-ray absorptiometry (DEXA) and observing the importance of accurate and consistent technique in patient setup and positioning of regions of interest in serial, surveillance DEXA imaging. We aim to stress the need to review the images acquired as well as the scores generated after bone mineral density analysis by both the technologists performing the studies and the medical reporters. This helps ensure regions of interest are adequate and the reports mention possible imaging appearances that may lead to inaccurate bone mineral density analysis such as bone metastases or degenerative change. Whilst DEXA does not aim to provide diagnostic quality anatomical images, it is still possible to identify additional pathology such as fractures or disease processes outside the skeleton. The selected cases include a previously undiagnosed fracture of the neck of femur, gall stones and bone metastases. Background: Fracture Liaison Services (FLS) have been developed to close the secondary fracture prevention gap. In younger individuals this assessment often requires a DXA scan. In our centre, we found that a proportion of patients were not attending for their DXA scans when arranged. This has economic implications to the service and also might lead to adverse outcomes for patients Objective: To assess the number of individuals who did not attend for their first and subsequent appointments for DXA scan. To assess whether individuals that did not attend for their DXA scan suffered further fractures. Methods: Between July 2014 and December 2017 we identified all individuals that did not attend for a DXA scan following referral by our Fracture Liaison Service at the Queen Alexandra Hospital Portsmouth. All of these patients were offered a second DXA appointment and we assessed the number who attended for this. Of the patients who had not attended for a DXA scan, we assessed whether there was evidence that they had suffered a further fracture. Results: Between July 2014 and December 2017, 3523 patients were referred by the Fracture Liaison Service for a DXA scan. Of these 422 (12%) did not attend for their first appointment. When a second appointment was offered only 42 (10%) attended for this. Of the 380 patients who did not attend either DXA appointment, 17 suffered a further fracture. Of these 11 were subsequently assessed and felt to require specific bone protection. Discussion: It has been noted that a small proportion of individuals offered a second DXA appointment attend. This has had implications on service provision. To avoid such a high proportion of non attendance Departments could consider further measures to improve adherence to appointments or consider informing patients that they will be offered one DXA appointment only unless specifically requested. Further work is required in this area to optimise resource utilisation with in the Fracture Liaison Services.
P62 RHEUMATOID ARTHRITIS IS ASSOCIATED WITH TRABECULAR BONE PARAMETERS ON HRPQCT
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/day dexamethasone, 14-28 days as induction therapy. Data were collected on calcium and Vitamin D status, osteoporosis risk factors and collated with DXA BMD scores and FRAX assessment where applicable. Results: 28(53%) patients had bone health assessment ([Vitamin D], DXA or both). 20 patients had DXA scans [12 <40yrs]. 1/12 had low BMD(LS Z score -2.0). 3/8 patients >40yrs had osteopenia. 13/22 patients had vitamin D assessment revealing suboptimal levels (<50nmol/l). Osteoporosis risk factors were present in 38/53; 9 current smokers, 8 ex-smokers. 1/53 sustained fractures whilst on treatment but these were not identified as fragility fractures.
Discussion: These data demonstrate bone health isn't optimally assessed when initiating glucocorticoid therapy. However, data shows a low incidence of low BMD. The high incidence of vitamin D insufficiency re-affirms the need for adequate initial assessment. Interpretation is limited by a retrospective analysis overestimating frequency of bone health assessment. Conclusion: This population is susceptible to iatrogenic osteoporosis and protocols lacked prospective consideration to optimise bone health. Prospective studies assessing bone health at baseline and after treatment would allow development of an assessment tool to quantify risk and treat appropriately. Background: Quantitative computed tomography (QCT) of the spine has the advantage that it can provide a measure of volumetric bone mineral density (vBMD) that excludes the posterior elements of the vertebrae. Objective: To (i) evaluate the ability of vBMD to discriminate between individuals with low areal bone mineral density (aBMD) by dual-energy x-ray absorptiometry (DXA) with and without vertebral fractures and (ii) compare this to the discriminatory ability of aBMD and trabecular bone score (TBS). Methods: We studied postmenopausal women (age = 68.8 ± 6.1 years) with an aBMD T-score <-1.0 at either the proximal femur or lumbar spine and either (i) ≥ 1 vertebral fracture (Group 1, n = 39) or (ii) no vertebral fractures and age-and aBMD-matched to those in Group 1 (Group 2, n = 34). Areal BMD was measured by DXA (QDR 4500A, Hologic) and TBS (Medimaps) was derived following DXA scan image reanalysis. Volumetric BMD of L1-L3 was determined by QCT using a GE Lightspeed 64 VCT and Mindways QCT Pro software. Differences in bone measurements between Group 1 and 2 were examined using General Linear Univariate Modelling approaches. The discriminatory ability (area under the curve (AUC)) of aBMD, TBS and vBMD was assessed using receiver operator characteristic (ROC) analysis. A comparison of ROCs was also performed. P<0.05 indicated statistical significance. Results: [ Table 1 ].
P76 Q U A N T I T A T I V E C O M P U T E D T O M O G R A P H Y DISCRIMINATES BETWEEN INDIVIDUALS WITH LOW
Discussion: Areal BMD and TBS could not discriminate between the women with and without vertebral fractures and mean values were similar for the two groups. However, vBMD was significantly lower in the vertebral fracture group and had a better discriminatory ability than aBMD and TBS.
Conclusion: QCT of the spine may discriminate well between individuals with and without vertebral fractures as it provides a 3D measure of bone mineral density and excludes the posterior elements of the vertebrae. Background: Depo-provera is a widely used form of contraception. It is a recognised cause of bone loss though there is evidence that any bone loss which occurs may be reversible on discontinuation. Current advice from the World Health Organisation (WHO) 2007 suggests no restriction on the use of Depo Provera if aged between 18 and 45 years though recommends that the overall benefits and risks are periodically reviewed. Objective: To identify whether women who receive Depo Provera contraceptive injections are counselled on the potential impact of these injections on bone health. Methods: A retrospective audit was undertaken in a large primary care practice in Salford. The clinical records of all patients who had received a Depo Provera injection over a six month period (between July 2017 and January 2018 were reviewed. Information about their age (at the time of injection) and the length of time that they had been on contraception were recorded. Also whether there was any documentation in the clinical record about counselling about the risk of bone loss. Individual consultations with the same patient were counted separately. Results: During the audit period 56 women received a depot injection with a total of 78 attendances. Their mean age was 30.4 years with a range of 16 years to 52 years. Two women were less than 18 years and 6 older than 45 years. The length of time that women had been on Depo Provera injections ranged from a single injection (n=7), up to 22 years. Review of the notes suggested that only 10% of patients had received counselling about their osteoporosis risk at each consultation. University of Aberdeen, Aberdeen, UK Introduction: Evidence supports managing patients over the age of 50, with fragility fracture, within a formal integrated system of care, incorporating a FLS. The NOS published clinical standards for osteoporosis and the prevention of fragility fractures in November 2017. Objective: To re-evaluate changes made to a local radiographer-led FLS, covering a large remote and rural population, assess any changes in FLS patient attendance, the detection rate of new-diagnosis osteoporosis within this cohort, and theoretical methods of reducing waiting times. Methods: Scanning data was reviewed over 6 months in 2017 for efficacy. Results: Identification and investigation: Patients >50-80 years with fragility fracture systematically identified via PACS to attend for bone health/fall assessment/DXA, directly appointed for scan. From this data, 47% of patients identified were eligible for scanning (ineligible -those in residential care, aged over 80, scanned in previous 2 years, deceased, and visitors to area). Patient uptake increased from 52% in 2015 to 79% 2017, consequently routine waiting times have increased. Assessments were conducted at around 16 weeks post fracture. For patients > 80 years, advice letters were sent directly to GPs. Background: There is a well established pathway for patients admitted to hospital with a hip fracture but not for patients admitted with other fractures. Having a fragility fracture puts patients at higher risk of further fractures, hospitalisation and increased risk of mortality. Patients who are offered bone protection post fracture are less likely to have a further fracture. Objectives: The improvement in the service was that a pharmacist prescriber would independently assess all patients with a fragility fracture and offer bone protection thus reducing the likelihood of a further fracture. Methods: A pharmacist prescriber was put into place on one hospital trauma ward. The pharmacist would independently assess any patient on that ward admitted with a non-hip fragility fracture and would join the hip fracture team to find out whether this would have a positive impact on hip fracture patients. The percentage of hip fracture patients offered a fragility fracture assessment would then be identified from the National Hip Fracture Database and compared with figures prior to pharmacist involvement. Results: 29 patients admitted with a fragility fracture were assessed by the pharmacist over 5 months. Of these patients 6 were hip fractures, 23 other fractures were assessed in addition to the current hip fracture pathway. All patients were offered treatment in the form of medication or referral for a DEXA scan and clinic follow-up. Independent data collected from National Hip Fracture Database showed improvement in patients offered bone assessment post hip fracture increased from 98 to 100%. Conclusions: Patients who sustained a fragility fracture were assessed for bone protection by a pharmacist and would not previously have been assessed. This shows there are patients who would benefit from this service and the addition of a pharmacist assessing bone protection can have a positive impact on reducing further fractures. Despite a hip fracture pathway being in place the addition of a pharmacist improved bone assessment.
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Omnya Ahmed, Anam Suddle, Tamir Malley, Karen Hicklin, Gordon MacDonald Rheumatology, Royal Berkshire NHS Foundation Trust, Reading, UK Background: Percutaneous vertebroplasty is a non-invasive radiologically guided procedure used to relieve pain caused by spinal compression fractures. It does not, however, improve bone strength or reduce fracture risk. It is therefore important to optimise treatment of the underlying osteoporosis. Objective: We collected data on patients referred for vertebroplasty in our trust, aiming to identify areas for improvement in order to develop an integrated care pathway for the management of symptomatic osteoporotic vertebral fractures that is more effective, compliant with NICE guidelines and ensures patients receive appropriate management of their osteoporosis, including eligibility and use of teriparatide specifically. Methods: We obtained a list of 60 referrals for vertebroplasty from 2016 to 2017. We extracted data on these patients from our hospital's Electronic Patient Record including: who diagnosed the fracture and when, underlying diagnosis, source of referral for vertebroplasty, waiting times for MRI and procedure, pain post procedure and management of osteoporosis (DEXA scanning, screening for secondary causes and management of bone protection). We also looked at eligibility for teriparatide. Results: The majority of referrals for vertebroplasty were made by the orthopaedic team (56%). Average waiting time from referral to procedure was 89 days (15-171 days). 72% of referrals proceeded to vertebroplasty and 72% of those patients reported improvement in symptoms. Bone protection was managed correctly overall in 52% of patients. Of the 17 patients who had fractured on first line therapy, 3 were switched to zoledronic acid and 8 were switched to denosumab. 8 were not eligible for teriparatide, 7 could have been eligible had they had a DEXA scan and only 1 was eligible and received teriparatide. Conclusion: Areas identified for improvement include: streamlining the referral pathway for vertebroplasty to reduce waiting times, having clear referral criteria and involving a spinal opinion in the pathway. The management of patients' osteoporosis can be optimised by producing clear guidelines for: treatment escalation, screening for secondary causes and requesting DEXA scans where appropriate, especially in the context of considering teriparatide as a second line agent. Objective: To test the effectiveness of using electronic searches of ED and radiology records to improve case-finding. Methods: Initially, the FLS provided a training session for ED advanced nurse practitioners followed by a link to an NHS email. For radiology, an audit of vertebral fracture reporting was presented followed by addition of an autotext phrase of 'fragility fracture requires FLS referral^. After 3 months, neither led to an increase in referrals. The FLS requested a bespoke query for all patients with a recorded fracture attending ED aged 50 years and over. In radiology, a musculoskeletal radiographer was employed to screen all patients who had undergone a CT/MRI/PET/Xray using a defined list of terms that could indicate a vertebral fracture. Data was extracted from the FLS database to quantify how many patients were identified by this process from 1.4.18 to 31.5.18 and their outcomes. Results: In the 2 months, 49 patients were identified from the ED pathway and 36 from the radiology pathway. The commonest sites of fracture in those identified in the ED pathway were distal radius (27%), vertebral (24%), pubic rami (19%), metatarsal (19%), rib (16%). Other fracture sites included ankle, clavicle, humerus, sacrum and wrist. From the radiology pathway, 61% of patients identified had one vertebral fracture and 20% had 3 or more vertebral fractures. None of these patients had been detected by the FLS. Overall, 3 patients declined or did not attend their FLS appointment. At the FLS appointment, all patients questioned were grateful for being identified. Conclusion: As trauma services are streamlined, electronic searching of the ED electronic patient record is possible and effective. Extending casefinding to include radiology reports leads to an appreciable number of patients with multiple fractures and at extremely high risk of fracture. This evaluation provides an assessment of the community-based Nottinghamshire Fracture Liaison & Osteoporosis Service ('NFLOS'), which launched in 2015 to provide a nurse-led, community service providing care for those who had sustained, or were at an elevated risk, of a low-trauma fracture ('fragility fracture'). The 2015 pilot service was launched as a test-bed in one specific Clinical Commissioning Group, with a patient population of c.147,000. In 2016, the service was invited to roll out across two other South Nottinghamshire Clinical Commissioning Groups, initially for an 18-month pilot period; patient population of c.460,000. The funding criteria for the additional CCGs differed in essence from the initial pilot CCG; in Year 2, the original pilot site expanded its investment to incorporate the identification / assessment / treatment and management of those considered to be at an elevated risk of fracture, whilst the two other CCGs restricted funding to those who had sustained initial fracture(s); however, at the time of writing, work is underway to align funding across South Nottinghamshire and ensure there is no disparity in service -parity should be established in March 2019. The service design reflected both local guidelines (Notts APC, 2016) and national recommendations (NOS 2017 , NOGG 2017 , NICE 2017 and was structured to incorporate the '5IQ' approach of the 2015 inaugural National Osteoporosis Society Clinical Standards document (NOS, 2015) . At present, only 37% of healthcare providers within the UK offer any form of fracture liaison service ('FLS'); additionally, the full scope of practice of an FLS has never been clearly defined and this has led to a fragmented, piecemeal approach with varying degrees of success (RCP, 2013 (RCP, & 2016 . NFLOS provides a quality, sustainable nurse-led service and embodies innovative ways of working to facilitate cohesive, cross-boundary working practices to drive up patient care and reduce healthcare spend. Background: We developed a unique management pathway to provide initial and ongoing management of osteoporosis in hip fracture patients using intravenous (IV) zoledronic acid. Compliance with oral bisphosphonates in high risk hip fracture patients is likely to be particularly poor and we are more frequently using IV zoledronic acid infusions two weeks post-fragility fracture. This requires annual follow-up for repeat infusions. Objective: To review inpatient referrals to the Metabolic Bone Centre (MBC) from the orthogeriatric team, to identify whether referrals were received, follow-up for IV zoledronic acid was offered and attended, and whether cognition influences this. Methods: We collected data for all patients referred to the MBC between 1st June 2016 and 28th February 2017 from the National Hip Fracture Database (NHFD), clinic letters and referral emails. Data was recorded and analysed using Microsoft Excel. Results: Of 118 patients referred, 107 were included in the analysis. 11 patients were excluded as there was no available NHFD data. 86 patients received their first dose of IV zoledronic acid two weeks post-operatively (80.4%) as an inpatient. The main reasons for not receiving this were discharge prior to 2 weeks, low Vitamin D despite high dose supplementation, or raised parathyroid hormone. All of the 21 patients who didn't receive it were invited to early follow-up. 2 patients died prior to this. 15 patients attended (78.9%) and 4 cancelled. 67 patients were invited to annual follow-up for repeat infusion. Of those not invited the reasons were that the patient had died (31), they had already cancelled further follow-up (4), renal function had declined (3), and no reason identified (2). 48 patients attended their appointment (71.6%). Those who did not attend had a lower abbreviated mental test, with an average of 5/10, than those who did attend (average 7/10) and post-operative 4AT delirium score was higher (3 compared to 2). Discussion: All referrals were received. Attendance at follow-up is generally good, although declines over times as expected. Non-attenders were more likely to have cognitive impairment. Conclusion: The majority of patients received their first zoledronic acid infusion as an inpatient. The onward referral pathway and service offered in Sheffield is successful. Background: NOGG recommends treatment be reviewed after 5 years of oral BP and treatment be continued in subjects >75yrs, with a history of hip or vertebral fracture, on oral steroids or who fractured on treatment. Objective: To examine the incidence of osteoporotic fracture (OF): vertebral, hip, pelvis, humerus or wrist, in a cohort of postmenopausal women who had received ≥5yrs of alendronate treatment during a monitored drug holiday. Methods: Fracture data was collected on 251 subjects -median of 9yrs alendronate, at discontinuation and at follow-up clinic appointments until treatment was restarted by the Clinician. Data was also collected on prior fractures. Results: A total of 41 fractures were recorded during follow-up, median follow-up 3 years (0.5-7yrs), average time to fracture 2.6±1.3 years. The most commonly occurring fracture was a vertebral fracture -29 vertebral fractures in 18 patients, mean time to fracture 2.6±1.2 yrs. Seven subjects with no risk factors went on to have an OF off treatment. Subjects >75yrs had significantly more OF (21.6 vs 8.6%; p=0.006) or vertebral fractures (5.1% vs. 13.8%; p=0.015) off treatment vs those <75yrs. Subjects >75yrs were more likely to have an OF OR 2.8 (95%CI 1.3-6.3; p=0.011). Sensitivity for predicting an osteoporotic fracture by age cutoff was 0.46, specificity 0.77. No difference in fracture rates between those with or without a history of hip or vertebral fracture and those with or without a fracture on treatment. Only 10 subjects in this group were on glucocorticoids and 1 subject fractured off treatment. When all subjects with a risk factor were combined they were significantly more likely to have an OF OR 2.7 (95%CI 1.1-6.6; p=0.03). Sensitivity for predicting an OF by NOGG risk factors was 0.73, specificity 0.47. Discussion: Not all subjects who had an OF off treatment had a risk factor. Prior hip/vertebral fracture, fracture on treatment or current steroid treatment did not significantly increase the risk of fracture by themselves in this cohort. Conclusion: Age >75yrs was the best single indicator for predicting OF in subjects off alendronate treatment. Including other risk factors increased the sensitivity but specificity declined. Background: Hip fracture is the commonest fracture in older people. It costs the NHS and social care £1 billion per year. Previous study showed that only 60% of patients with hip fracture who received bone protection treatment.
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Objective: To evaluate the quality of bone health assessment and management delivered to hip fracture patients in a tertiary centre. (above the 60 year-old) who were admitted for hip fracture was undertaken, with a one-month re-audit (from 15 th December 2017 to 15 th January 2018) was carried out using identical methods after implementing a change. A Best Practise Tariff (BPT) checklist was included in all patients' clinical summary. We aimed to complete all sections during patients' stay and included all the information in discharge summary. We excluded patients who passed away during this admission and patients who had pathological fracture. Results: In baseline audit, 82 patients were admitted during study period and 4 of them were excluded as per above criteria. (M:F= 30: 48; ). In re-audit, 35 patients were admitted during study period and 3 of them were excluded as per above criteria. ( M:F=8:24; Mean age: 80.1 [Range:62-94]) Table 1 showed the significant improvement of bone health assessment and management in patients with hip fracture after we implemented change. Discussion: The reaudit showed the importance of further strategies to ensure that bone protection treatment is offered to hip fracture patients who warrant it. It also highlighted the need to improve communication with primary care to ensure good compliance of bone protection treatment. Conclusion: Use of BPT checklist in clinical summary has improved the care we delivered to patients with hip fracture significantly. References:
(1) National Hip Fracture Database Annual Report 2017, Royal College of Physician. Osteoporos Int (2018) 29 (Suppl 2):S601-S649had been on a cycle of 10 days on steroid treatment followed by 10 days off (doses of 30 mg/day and 27.5 mg/day during the active treatment phase). All patients had previously sustained vertebral fractures, and 3 had sustained appendicular fractures. Bone density was significantly low for age in all patients (mean spine BMD Z-score -3.3, and mean total hip Z-score -2.7). All patients were on bone protection in the form of bisphosphonate medication (IV Zoledronate-3, oral Risedronate-1). Our experience demonstrates that osteoporosis is common in adults with DMD. Patients should have spinal imaging with X-ray or VFA to identify vertebral fractures. At present bisphosphonate appear to be the standard of care for patients as they transition from paediatric care into adult services, but the risks and benefits of prolonged treatment into adulthood needed to be determined. Further studies could also explore the role for other drugs such as Denosumab or Teriparatide in this patient population. 
Materials and Methods:
The patients were referred for bone density scan by GPs or hospital clinicians. The clinician reporting on DXA scan also completed a database sheet. We analysed the database activity for a period of 4 years from September 2009-August 2013. Discussion: Our hospital caters for a population of 250 000. During the 4 year period, a total of 8080 patients were scanned. 5620 (69%) were referred by GPs and remaining 2460 by hospital clinicians, of which only 232 (3%) were referred by orthopaedic teams. As expected, the majority -6804 (84%) -were female patients. In 1661 (20.5%) of 8080 patients the indication for referral was history of previous low trauma fracture. A majority of these (916) were referred by GPs. Orthopaedic department contributed by 154 referrals highlighting the need for a local Fracture Liaison Service and pathways for referrals. Of these, 487 were vertebral and 1174 non-vertebral fractures. Of 487 patients with vertebral fractures, 390 (80%) had either osteopenia or osteoporosis. These patients need early intervention, assessment and treatment. 448 out of 487 vertebral fracture patients were subsequently referred to local Bone Health Clinic. Of 1174 non-vertebral fractures, 803 (68%) had abnormal bone density. This data underlined the low referral rates from fracture clinics and need for Fracture Liaison Service. On basis of evidence a case was successfully made for Fracture Liaison Service, which was commissioned. This subsequently led to appointment of FLS specialist nurse in 2015.
Conclusion: The referral rates from fracture clinics for Bone Density scanning conventionally remain low. These patients however have high incidence of abnormal BMD and need further assessment of their bone health. Data such as this can be used to make a case for Fracture Liaison service with local commissioners.
